<SEC-DOCUMENT>0001047469-19-005237.txt : 20190916
<SEC-HEADER>0001047469-19-005237.hdr.sgml : 20190916
<ACCEPTANCE-DATETIME>20190916061425
ACCESSION NUMBER:		0001047469-19-005237
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20190916
DATE AS OF CHANGE:		20190916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbbVie Inc.
		CENTRAL INDEX KEY:			0001551152
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				320375147
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227316
		FILM NUMBER:		191093622

	BUSINESS ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
		BUSINESS PHONE:		(847) 932-7900

	MAIL ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a2239674z424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg48901_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#bg48902_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No&nbsp;333-227316  </B></FONT></P>

<P style="font-family:times;"><FONT COLOR="#EF505F" SIZE=2><B>The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been
filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to
buy these securities in any jurisdiction where such offer or sale is not permitted. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT COLOR="#EF505F" SIZE=2><B>SUBJECT TO COMPLETION, DATED SEPTEMBER 16, 2019</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> PRELIMINARY PROSPECTUS SUPPLEMENT<BR>
(To Prospectus dated September&nbsp;13, 2018)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>AbbVie&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% SENIOR NOTES DUE 20&nbsp;&nbsp;<BR>
&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% SENIOR NOTES DUE 20&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Interest on each series of Notes is payable on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of each year,
commencing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie&nbsp;Inc., a Delaware corporation (the "Company" or the "Issuer"), is offering &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aggregate principal
amount of its
&nbsp;&nbsp;&nbsp;&nbsp;% senior notes due 20&nbsp;&nbsp;&nbsp;&nbsp;(the "20&nbsp;&nbsp;&nbsp;&nbsp;Notes") and &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aggregate principal amount of its&nbsp;&nbsp;&nbsp;&nbsp;%
senior notes due
20&nbsp;&nbsp;&nbsp;&nbsp;(the "20&nbsp;&nbsp;&nbsp;&nbsp;Notes" and together with the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes, the "Notes"). Each of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes and the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes is referred to as a
"series" of Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Notes will be unsecured, unsubordinated obligations of the Company and will rank equally in right of payment with all of the Company's existing and future unsecured, unsubordinated
indebtedness, liabilities and other obligations. The Notes will be issued in minimum denominations of &euro;100,000 and in integral multiples of &euro;1,000 in excess thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently
there is no public market for any series of the Notes. We intend to apply to list the Notes on the New York Stock Exchange. The listing application will be subject to approval
by the New York Stock Exchange. If such listing is obtained, we have no obligation to maintain such listing and we may delist any series of the Notes at any time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company intends to use the net proceeds from the sale of the Notes, together with cash on hand, (i)&nbsp;to redeem, satisfy and discharge or repay at maturity all of its 0.375%
senior notes due 2019 (the "2019 Notes") in an aggregate outstanding principal amount of &euro;1.4&nbsp;billion, and to pay any premium and accrued interest in respect thereof, and/or
(ii)&nbsp;for general corporate purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company may redeem some or all of each series of Notes at any time at the redemption prices described in this prospectus supplement under the caption "Description of
Notes&#151;Optional Redemption." In addition, the Company may redeem each series of Notes in whole, but not in part, at its option, in the event of certain developments affecting U.S. taxation
as described under the heading "Description of Notes&#151;Redemption for Tax Reasons." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in the Notes involves risks. Please read "Risk Factors" included or incorporated by reference herein, as described beginning on
page&nbsp;S-17 of this prospectus supplement.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=7 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Public<BR>
offering price(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Underwriting<BR>
discounts</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proceeds, before<BR>
expenses, to us</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=7 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Per 20&nbsp;&nbsp;&nbsp;&nbsp;Note</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=7 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per 20&nbsp;&nbsp;&nbsp;&nbsp;Note</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=7 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=7 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Plus
accrued interest from, and including,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, if settlement occurs after that date.  </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
this prospectus supplement. Any representation to the contrary is a criminal offense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Notes will initially be represented by one or more global notes in registered form ("Global Notes") which will be registered in the name of a nominee of, and deposited with, a common
depositary for Euroclear Bank&nbsp;SA/NV ("Euroclear") and Clearstream Banking&nbsp;S.A. ("Clearstream, Luxembourg"). The underwriters expect to deliver the Notes through the book-entry system of
Euroclear and Clearstream, Luxembourg against payment on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, which is
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;London business day following the date of this prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>Joint Book-Running Managers  </I></B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="145pt" style="font-family:times;"></TD>
<TD WIDTH="19%" style="font-family:times;"></TD>
<TD WIDTH="178pt" style="font-family:times;"></TD>
<TD WIDTH="19%" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><B>Morgan Stanley<BR> </B></FONT><FONT SIZE=2><I>(Global Coordinator)</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><B> BofA Merrill Lynch</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><B> HSBC</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The
date of this prospectus supplement is September&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=463674,FOLIO='blank',FILE='DISK110:[19ZCG1.19ZCG48901]BC48901A.;13',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg48901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG48901A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg48901_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG48901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_about_this_prospectus_supplement"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_about_this_prospectus_supplement"><FONT SIZE=2><BR>
S-1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_where_to_obtain_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE TO OBTAIN MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_where_to_obtain_more_information"><FONT SIZE=2>S-2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_information_incorporated_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION INCORPORATED BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_information_incorporated_by_reference"><FONT SIZE=2>S-2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_industry_and_market_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INDUSTRY AND MARKET DATA</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_industry_and_market_data"><FONT SIZE=2>S-3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_notice_to_residents_of_the_united_kingdom"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NOTICE TO RESIDENTS OF THE UNITED KINGDOM</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_notice_to_residents_of_the_united_kingdom"><FONT SIZE=2>S-4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_notice_to_residents_of_the_european_economic_area"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NOTICE TO RESIDENTS OF THE EUROPEAN ECONOMIC AREA</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_notice_to_residents_of_the_european_economic_area"><FONT SIZE=2>S-4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_stabilization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>STABILIZATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_stabilization"><FONT SIZE=2>S-5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48901_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48901_forward-looking_statements"><FONT SIZE=2>S-6</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48901_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SUMMARY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48901_summary"><FONT SIZE=2>S-7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48901_selected_historical_co__cc402261"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF ABBVIE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48901_selected_historical_co__cc402261"><FONT SIZE=2>S-12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48901_the_offering"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE OFFERING</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48901_the_offering"><FONT SIZE=2>S-13</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da48901_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da48901_risk_factors"><FONT SIZE=2>S-17</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc48901_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc48901_use_of_proceeds"><FONT SIZE=2>S-24</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc48901_currency_conversion"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CURRENCY CONVERSION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc48901_currency_conversion"><FONT SIZE=2>S-25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc48901_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAPITALIZATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc48901_capitalization"><FONT SIZE=2>S-26</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc48901_description_of_notes"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF NOTES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc48901_description_of_notes"><FONT SIZE=2>S-27</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di48901_material_u.s._federal_income_tax_considerations"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di48901_material_u.s._federal_income_tax_considerations"><FONT SIZE=2>S-46</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk48901_underwriting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITING</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk48901_underwriting"><FONT SIZE=2>S-52</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm48901_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm48901_legal_matters"><FONT SIZE=2>S-58</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm48901_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm48901_experts"><FONT SIZE=2>S-59</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PROSPECTUS</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48902_about_this_prospectus"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48902_about_this_prospectus"><FONT SIZE=2><BR>
1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48902_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48902_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48902_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48902_prospectus_summary"><FONT SIZE=2>3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48902_information_incorporated_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION INCORPORATED BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48902_information_incorporated_by_reference"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48902_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48902_where_you_can_find_more_information"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48902_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48902_risk_factors"><FONT SIZE=2>6</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48902_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48902_use_of_proceeds"><FONT SIZE=2>7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48902_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIO OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48902_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>8</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_description_of_debt_securities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_description_of_debt_securities"><FONT SIZE=2>9</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_plan_of_distribution"><FONT SIZE=2>12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_legal_matters"><FONT SIZE=2>14</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_experts"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=34609,FOLIO='i',FILE='DISK110:[19ZCG1.19ZCG48901]BG48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bi48901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_about_this_prospectus_supplement"> </A>
<A NAME="toc_bi48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;13, 2018, we filed with the SEC a registration statement on Form&nbsp;S-3 utilizing a shelf registration process relating
to the securities described in this prospectus supplement, which became effective upon filing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
document is in two parts. The first part is the prospectus supplement, which describes the specific terms of the Notes we are offering and certain other matters relating to us and
our financial condition. The second part, the accompanying prospectus, gives more general information about debt securities that we may offer from time to time, some of which may not apply to the
Notes we are offering. The rules of the SEC allow us to incorporate by reference information into this prospectus supplement. This information incorporated by reference is considered to be a part of
this prospectus supplement, and information that we file later with the SEC, to the extent incorporated by reference, will automatically update and supersede this information. See "Information
Incorporated by Reference." You should read this prospectus supplement along with the accompanying prospectus, as well as the documents
incorporated by reference. If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus
supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not, and the underwriters have not, authorized any dealer, salesman or other person to provide you with any information or to make any representation other than those contained
or incorporated by reference into this prospectus supplement or the accompanying prospectus and any free writing prospectus prepared by or on behalf of us. We take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. This
prospectus supplement and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the Notes offered hereby, nor do this
prospectus supplement and the accompanying prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make
such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus supplement and the accompanying prospectus is accurate on any date subsequent
to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference,
even though this prospectus supplement and the accompanying prospectus is delivered or securities are sold on a later date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise provided herein, as used in this prospectus supplement, the terms "Issuer" and "Company" refer to AbbVie&nbsp;Inc., a Delaware corporation, and not to any of its
subsidiaries; and "AbbVie," "we," "us" and "our" refer to AbbVie&nbsp;Inc. and its consolidated subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=541179,FOLIO='S-1',FILE='DISK110:[19ZCG1.19ZCG48901]BI48901A.;14',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_bi48901_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_where_to_obtain_more_information"> </A>
<A NAME="toc_bi48901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE TO OBTAIN MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3 with respect to the securities offered hereby. This prospectus supplement
does not contain all the information set forth in the registration statement, parts of which are omitted in accordance with the rules and regulations of the SEC. For further information with respect
to us and the securities offered hereby, reference is made to the registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and special reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet from the SEC's website
at www.sec.gov, or our website at www.abbvie.com. </FONT><FONT SIZE=2><B>Our website and the information contained therein or connected thereto shall not be deemed to be incorporated into this
prospectus supplement or registration statement of which this prospectus supplement forms&nbsp;a part and you should not rely on any such information in making your investment
decision.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_information_incorporated_by_reference"> </A>
<A NAME="toc_bi48901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  INFORMATION INCORPORATED BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" information we file with them, which means that we can disclose important information to you by
referring you to those documents. The information that we incorporate by reference that is filed prior to the date of this prospectus supplement is considered to be part of this prospectus supplement,
and information that we file after the date of this prospectus supplement and prior to the completion of the offering of the Notes pursuant to this prospectus supplement will automatically update and
supersede information included or previously incorporated by reference into this prospectus supplement from the date we file the document containing such information. Any statement so modified or
superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. Except to the extent furnished and not filed with the SEC pursuant to
Items&nbsp;2.02 or 7.01 of Form&nbsp;8-K or as otherwise permitted by the SEC rules, we incorporate by reference the documents listed below and any future filings we will make with the SEC under
Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and such documents shall be deemed to be incorporated by reference into this
prospectus supplement and to be a part of this prospectus supplement from the respective dates of filing thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
documents we incorporate by reference into this prospectus supplement are: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>AbbVie's
Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/abbv-20181231x10k.htm">Form&nbsp;10-K for the year
ended December&nbsp;31, 2018, filed with the SEC on February&nbsp;27, 2019</A> (including portions of our Definitive
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465919016835/a19-2500_3defa14a.htm">Proxy Statement on Schedule&nbsp;14A, filed with the SEC on March&nbsp;22,
2019);</A>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>AbbVie's
Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2019 and June&nbsp;30, 2019, filed with the SEC on
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/abbv-20190331x10q.htm">May&nbsp;3, 2019</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm">August&nbsp;5, 2019</A>, respectively; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>AbbVie's
Current Reports on Form&nbsp;8-K as filed with the SEC on each of
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465919000837/a19-1169_18k.htm">January&nbsp;4, 2019</A>
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465919000836/a19-1169_28k.htm">(Two Filing)</A> (both Current Reports filed on such date),
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465919027194/a19-9433_18k.htm">May&nbsp;6, 2019</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465919037446/a19-12093_18k.htm">June&nbsp;25, 2019</A> (excluding Exhibit&nbsp;99.1),
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465919040574/a19-12093_28k.htm">July&nbsp;16, 2019</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000141057819000980/0001410578-19-000980-index.htm">August&nbsp;30, 2019</A> and September&nbsp;16, 2019 (only the
Current Report that includes Item&nbsp;8.01 and 9.01 disclosure). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Documents
incorporated by reference are available from us, without charge, excluding all exhibits unless specifically incorporated by reference in the documents. You may obtain documents
incorporated by reference into this prospectus supplement by writing to us at the following address or by calling us at the telephone number listed below: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>AbbVie&nbsp;Inc.<BR>
1 North Waukegan Road<BR>
North Chicago, Illinois 60064<BR>
Attention: Investor Relations<BR>
(847)&nbsp;932-7900<BR>
http://investors.abbvie.com </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=891559,FOLIO='S-2',FILE='DISK110:[19ZCG1.19ZCG48901]BI48901A.;14',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_bi48901_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_industry_and_market_data"> </A>
<A NAME="toc_bi48901_4"> </A>
<BR></FONT><FONT SIZE=2><B>  INDUSTRY AND MARKET DATA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement and the accompanying prospectus, and any document incorporated by reference into this prospectus supplement and the
accompanying prospectus, may include industry and trade association data, forecasts and information that we have prepared based, in part, upon data, forecasts and information obtained from independent
trade associations, industry publications and surveys and other information available to us. Some data is also based on our good-faith estimates, which are derived from management's knowledge of the
industry and independent sources. Industry publications and surveys and forecasts generally state that the information contained in these materials has been obtained from sources believed to be
reliable. Although we believe these sources are reliable, we have not independently verified the information. In certain of the markets in which we operate, it may be difficult to directly ascertain
industry or market data. Unless otherwise noted, statements as to our market share and market position are approximated and based on management experience and estimates using the above-mentioned
third-party data combined with our internal analysis and estimates. While we are not aware of any misstatements regarding our industry data presented in the applicable documents, our estimates involve
risks and uncertainties and are subject to change based on various factors, including those discussed under the heading "Risk Factors" in this prospectus supplement and the accompanying prospectus, as
well as the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. Similarly, while we believe our internal research is reliable, such research has not
been verified by any independent sources. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=906745,FOLIO='S-3',FILE='DISK110:[19ZCG1.19ZCG48901]BI48901A.;14',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_bi48901_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_notice_to_residents_of_the_united_kingdom"> </A>
<A NAME="toc_bi48901_5"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTICE TO RESIDENTS OF THE UNITED KINGDOM    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS MAY ONLY BE COMMUNICATED OR CAUSED TO BE COMMUNICATED IN THE UNITED KINGDOM TO
PERSONS HAVING PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND QUALIFYING AS INVESTMENT PROFESSIONALS UNDER ARTICLE 19 (INVESTMENT PROFESSIONALS) OF THE FINANCIAL SERVICES AND MARKETS
ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") OR TO PERSONS FALLING WITHIN ARTICLE 49 (2)(A) TO (D)&nbsp;(HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC) OF THE
ORDER OR TO ANY OTHER PERSON TO WHOM THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS MAY OTHERWISE LAWFULLY BE COMMUNICATED OR CAUSED TO BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING
REFERRED TO AS "RELEVANT PERSONS"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEITHER
THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS NOR THE NOTES ARE OR WILL BE AVAILABLE TO PERSONS WHO ARE NOT RELEVANT PERSONS AND THIS PROSPECTUS SUPPLEMENT AND THE
ACCOMPANYING PROSPECTUS MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING
PROSPECTUS RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. THE COMMUNICATION OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS TO ANY
PERSON IN THE UNITED KINGDOM WHO IS NOT A RELEVANT PERSON IS UNAUTHORIZED AND MAY CONTRAVENE THE FINANCIAL SERVICES AND MARKETS ACT 2000, AS AMENDED (THE "FSMA"). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_mifid_ii_product_governance_/___mif03237"> </A>
<A NAME="toc_bi48901_6"> </A>
<BR></FONT><FONT SIZE=2><B>  MIFID II PRODUCT GOVERNANCE / PROFESSIONAL INVESTORS AND ECPS ONLY TARGET MARKET    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SOLELY FOR THE PURPOSES OF EACH MANUFACTURER'S PRODUCT APPROVAL PROCESS, THE TARGET MARKET ASSESSMENT IN RESPECT OF THE NOTES HAS LED TO THE
CONCLUSION THAT: (I)&nbsp;THE TARGET MARKET FOR THE NOTES IS ELIGIBLE COUNTERPARTIES AND PROFESSIONAL CLIENTS ONLY, EACH AS DEFINED IN DIRECTIVE 2014/65/EU (AS AMENDED, "MIFID II"); AND
(II)&nbsp;ALL CHANNELS FOR DISTRIBUTION OF THE NOTES TO ELIGIBLE COUNTERPARTIES AND PROFESSIONAL CLIENTS ARE APPROPRIATE. ANY PERSON SUBSEQUENTLY OFFERING, SELLING OR RECOMMENDING THE NOTES (A
"DISTRIBUTOR") SHOULD TAKE INTO CONSIDERATION THE MANUFACTURERS' TARGET MARKET ASSESSMENT; HOWEVER, A DISTRIBUTOR SUBJECT TO MIFID II IS RESPONSIBLE FOR UNDERTAKING ITS OWN TARGET MARKET ASSESSMENT IN
RESPECT OF THE NOTES (BY EITHER ADOPTING OR
REFINING THE MANUFACTURERS' TARGET MARKET ASSESSMENT) AND DETERMINING APPROPRIATE DISTRIBUTION CHANNELS. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_notice_to_residents_of_the_european_economic_area"> </A>
<A NAME="toc_bi48901_7"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTICE TO RESIDENTS OF THE EUROPEAN ECONOMIC AREA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE NOTES ARE NOT INTENDED TO BE OFFERED, SOLD OR OTHERWISE MADE AVAILABLE TO AND SHOULD NOT BE OFFERED, SOLD OR OTHERWISE MADE AVAILABLE TO ANY
RETAIL INVESTOR IN THE EUROPEAN ECONOMIC AREA ("EEA"). FOR THESE PURPOSES, A RETAIL INVESTOR MEANS A PERSON WHO IS ONE (OR MORE) OF: (I)&nbsp;A RETAIL CLIENT AS DEFINED IN POINT (11)&nbsp;OF
ARTICLE 4(1) OF MIFID&nbsp;II; (II)&nbsp;A CUSTOMER WITHIN THE MEANING OF DIRECTIVE 2002/92/EC ON INSURANCE MEDIATION, AS AMENDED AND SUPERSEDED, WHERE THAT CUSTOMER </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=771108,FOLIO='S-4',FILE='DISK110:[19ZCG1.19ZCG48901]BI48901A.;14',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_bi48901_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>WOULD
NOT QUALIFY AS A PROFESSIONAL CLIENT AS DEFINED IN POINT (10)&nbsp;OF ARTICLE 4(1) OF MIFID II; OR (III)&nbsp;NOT A QUALIFIED INVESTOR AS DEFINED IN REGULATION (EU)&nbsp;2017/1129 (AS
AMENDED, THE "PROSPECTUS REGULATION"). CONSEQUENTLY NO KEY INFORMATION DOCUMENT REQUIRED BY REGULATION (EU)&nbsp;1286/2014 (AS AMENDED, THE "PRIIPS REGULATION") FOR OFFERING OR SELLING THE NOTES OR
OTHERWISE MAKING THEM AVAILABLE TO RETAIL INVESTORS IN THE EEA HAS BEEN PREPARED AND THEREFORE OFFERING OR SELLING THE NOTES OR OTHERWISE MAKING THEM AVAILABLE TO ANY RETAIL INVESTOR IN THE EEA MAY BE
UNLAWFUL UNDER THE PRIIPS REGULATION. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_stabilization"> </A>
<A NAME="toc_bi48901_8"> </A>
<BR></FONT><FONT SIZE=2><B>  STABILIZATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN CONNECTION WITH THE ISSUE OF THE NOTES, MORGAN STANLEY&nbsp;&amp;&nbsp;CO. INTERNATIONAL&nbsp;PLC (IN THIS CAPACITY, THE "STABILIZING
MANAGER") (OR ANY PERSON ACTING ON ITS BEHALF) MAY OVER-ALLOT NOTES OR EFFECT TRANSACTIONS WITH A VIEW TO SUPPORTING THE MARKET PRICE OF THE NOTES AT A LEVEL HIGHER THAN THAT WHICH MIGHT OTHERWISE
PREVAIL. HOWEVER, STABILIZATION MAY NOT NECESSARILY OCCUR. ANY STABILIZATION ACTION MAY BEGIN ON OR AFTER THE DATE ON WHICH ADEQUATE PUBLIC DISCLOSURE OF THE TERMS OF THE OFFER OF THE NOTES IS MADE,
AND, IF BEGUN, MAY CEASE AT ANY
TIME, BUT IT MUST END NO LATER THAN THE EARLIER OF&nbsp;30 DAYS AFTER THE ISSUE DATE OF THE NOTES AND 60 DAYS AFTER THE DATE OF THE ALLOTMENT OF THE NOTES. ANY STABILIZATION ACTION OR OVER-ALLOTMENT
MUST BE CONDUCTED BY THE STABILIZING MANAGER (OR ANY PERSON ACTING ON ITS BEHALF) IN ACCORDANCE WITH ALL APPLICABLE LAWS AND RULES. SEE "UNDERWRITING." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=672084,FOLIO='S-5',FILE='DISK110:[19ZCG1.19ZCG48901]BI48901A.;14',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_bi48901_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48901_forward-looking_statements"> </A>
<A NAME="toc_bi48901_9"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some statements in this prospectus supplement, the accompanying prospectus, any free writing prospectus and the documents incorporated by
reference into this prospectus supplement or the accompanying prospectus may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project," and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to
intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations
applicable to our industry, the failure of AbbVie to consummate the proposed acquisition (the "Acquisition") of Allergan&nbsp;plc ("Allergan") and the failure to realize the expected benefits of the
proposed Acquisition. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie's experience and perception of historical trends, current conditions,
business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties
because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this prospectus supplement, the
accompanying prospectus, any free writing prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus could cause AbbVie's plans with respect
to Allergan, Allergan's or AbbVie's actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking
statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct
and persons reading this prospectus supplement, the accompanying prospectus, any free writing prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying
prospectus are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this prospectus supplement. Additional information about economic,
competitive, governmental, technological and other factors that may affect AbbVie is set forth in Item&nbsp;1A, "Risk Factors," in AbbVie's
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/abbv-20181231x10k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018</A>, and in other documents
that we subsequently file with the SEC that update, supplement or supersede such information, all of which are incorporated by reference into this prospectus supplement and the accompanying
prospectus. AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
forward-looking statements in this prospectus supplement, the accompanying prospectus, any free writing prospectus and the documents incorporated by reference into this prospectus
supplement or the accompanying prospectus are based upon information available to AbbVie as of the date of this prospectus supplement and, while believed to be true when made, may ultimately prove to
be incorrect. Subject to any obligations under applicable law, AbbVie undertakes no obligation to update any forward-looking statement whether as a result of new information, future developments or
otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to
AbbVie or any person acting on its behalf are expressly qualified in their entirety by this paragraph. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
carefully review and consider the various disclosures made in this prospectus supplement and the accompanying prospectus and any free writing prospectus and documents incorporated
by reference into this prospectus supplement or the accompanying prospectus that attempt to advise interested parties of the risks and factors that may affect our business, prospects and results of
operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=8,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=418364,FOLIO='S-6',FILE='DISK110:[19ZCG1.19ZCG48901]BI48901A.;14',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca48901_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48901_summary"> </A>
<A NAME="toc_ca48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary highlights information contained elsewhere in this prospectus supplement and the documents we
incorporate by reference and is qualified in its entirety by the more detailed information and consolidated financial statements included elsewhere in this prospectus supplement, the accompanying
prospectus and the documents we incorporate by reference into this prospectus supplement. This summary is not complete and may not contain all of the information that may be important to you. You
should carefully read the following summary together with the entire prospectus supplement, including the "Risk Factors" section, the accompanying prospectus and our consolidated financial statements
and notes to those statements, before making an investment decision.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48901_our_business"> </A>
<A NAME="toc_ca48901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Our Business    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie is a global, research-based biopharmaceutical company. AbbVie uses its expertise, dedicated people and unique approach to innovation to
develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in
rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus ("HCV") and human immunodeficiency virus ("HIV"); neurological disorders, such
as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.
AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in
cystic fibrosis and women's health. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's
products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from
AbbVie-owned distribution centers and public warehouses. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales
directly to pharmacies and patients. Outside the United States, AbbVie sells products primarily to customers or through distributors, depending on the market served. Certain products are co-marketed
or co-promoted with other companies. AbbVie has approximately 30,000 employees. AbbVie operates in one business segment&#151;pharmaceutical products. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan. See "&#151;Our Acquisition of
Allergan." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48901_our_products"> </A>
<A NAME="toc_ca48901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Our Products    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's portfolio of products includes a broad line of therapies that address some of the world's most complex and serious diseases. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=296364,FOLIO='S-7',FILE='DISK110:[19ZCG1.19ZCG48901]CA48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ca48901_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immunology products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's immunology products help provide improved care for people living with immune-mediated conditions.
These products are: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HUMIRA.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;HUMIRA (adalimumab) is a biologic therapy administered as a subcutaneous injection. It is approved to treat the following
autoimmune diseases
in the United States, Canada, and Mexico (collectively, "North America"), and in the European Union: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="188pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Condition

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal Markets </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rheumatoid arthritis (moderate to severe)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Psoriatic arthritis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ankylosing spondylitis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adult Crohn's disease (moderate to severe)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plaque psoriasis (moderate to severe)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Juvenile idiopathic arthritis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ulcerative colitis (moderate to severe)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Axial spondyloarthropathy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pediatric Crohn's disease (moderate to severe)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hidradenitis Suppurativa</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pediatric enthesitis-related arthritis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>European Union</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-infectious intermediate, posterior and panuveitis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>North America, European Union</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HUMIRA
is also approved in Japan for the treatment of intestinal Beh&ccedil;et"s disease. HUMIRA is sold in numerous other markets worldwide, including Japan, China, Brazil and
Australia, and accounted for approximately 61% of AbbVie's total net revenues in 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SKYRIZI.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;SKYRIZI (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor that is approved in the United States and the European
Union for the
treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RINVOQ.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;RINVOQ (upadacitinib) is a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to
severely
active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (MTX-IR). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oncology products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's oncology products target some of the most complex and difficult-to-treat cancers. These products
are: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IMBRUVICA.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;IMBRUVICA (ibrutinib) is an oral, once-daily therapy that inhibits a protein called Bruton"s tyrosine kinase. IMBRUVICA was
one of the
first medicines to receive a United States Food and Drug Administration ("FDA") approval after being granted a Breakthrough Therapy Designation and is one of the few therapies to receive four separate
designations. IMBRUVICA currently is approved for the treatment of adult patients with:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Chronic lymphocytic leukemia ("CLL")/Small lymphocytic lymphoma ("SLL") and CLL/SLL with 17p deletion; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mantle cell lymphoma who have received at least one prior therapy*; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Waldenstr&ouml;m's macroglobulinemia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy*; and </FONT></DD></DL>
</UL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Accelerated
approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of
clinical benefit in confirmatory trials. </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=860658,FOLIO='S-8',FILE='DISK110:[19ZCG1.19ZCG48901]CA48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ca48901_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Chronic graft versus host disease after failure of one or more lines of systemic therapy. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VENCLEXTA.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;VENCLEXTA (venetoclax) is a BCL-2 inhibitor used to treat adults with CLL or SLL, with or without 17p deletion, who have
received at least
one prior treatment. In addition, VENCLEXTA is used in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia who are
75&nbsp;years of age or older or have other medical conditions that prevent the use of standard chemotherapy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Virology Products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's virology products address unmet needs for patients living with HCV and HIV. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's
HCV products are: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MAVYRET/MAVIRET.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;MAVYRET (glecaprevir/pibrentasvir) is approved in the United States and European Union (MAVIRET) for the treatment of
patients with
chronic HCV genotype&nbsp;1-6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). It is also indicated for the treatment of adult patients with HCV genotype&nbsp;1
infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. It is an 8-week, pan-genotypic treatment for patients without
cirrhosis and who are new to treatment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VIEKIRA PAK AND TECHNIVIE.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) is an all-oral, short-course,
interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype&nbsp;1 chronic HCV, including those with compensated cirrhosis. In Europe, VIEKIRA PAK is
marketed as VIEKIRAX&nbsp;+&nbsp;EXVIERA and is approved for use in patients with genotype&nbsp;1 and genotype&nbsp;4 HCV. AbbVie's TECHNIVIE (ombitasvir, paritaprevir and ritonavir) is
FDA-approved for use in combination with ribavirin for the treatment of adults with genotype&nbsp;4 HCV infection in the United States. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional Virology products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's additional virology products include: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SYNAGIS.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;SYNAGIS (palivizumab) is a product marketed by AbbVie outside of the United States that protects at-risk infants from severe
respiratory
disease caused by respiratory syncytial virus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KALETRA.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;KALETRA (lopinavir/ritonavir), which is also marketed as Aluvia in emerging markets, is a prescription anti-HIV-1 medicine
that contains two
protease inhibitors: lopinavir and ritonavir. KALETRA is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NORVIR.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;NORVIR (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment
of HIV-1
infection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Metabolics/Hormones products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Metabolic and hormone products target a number of conditions, including testosterone deficiency
due to certain
underlying conditions, exocrine pancreatic insufficiency and hypothyroidism. These products include: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CREON.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;CREON (pancrelipase) is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients
with cystic
fibrosis, chronic pancreatitis and several other conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Synthroid.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Synthroid (levothyroxine sodium tablets, USP) is used in the treatment of hypothyroidism. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AndroGel.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;AndroGel (testosterone gel) is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone due
to certain
underlying conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
has the rights to sell AndroGel, CREON and Synthroid only in the United States. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=482715,FOLIO='S-9',FILE='DISK110:[19ZCG1.19ZCG48901]CA48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ca48901_1_10"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Endocrinology products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Lupron (leuprolide acetate), which is also marketed as Lucrin and LUPRON DEPOT, is a product for the
palliative treatment of
advanced prostate cancer, treatment of endometriosis and central precocious puberty and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily
subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other products.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's other products include: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ORILISSA.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;ORILISSA (elagolix) is the first and only orally-administered, nonpeptide small molecule gonadotropin-releasing hormone
(GnRH) antagonist
specifically developed for women with moderate to severe endometriosis pain. The FDA approved ORILISSA under priority review. It represents the first FDA-approved oral treatment for the management of
moderate to severe pain associated with endometriosis in over a decade. ORILISSA inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration
results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, leading to decreased blood concentrations of ovarian sex hormones, estradiol and progesterone. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duopa and Duodopa</I></FONT><FONT SIZE=2> (carbidopa and levodopa).&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's
disease is marketed
as Duopa in the United States and as Duodopa outside of the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sevoflurane.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Sevoflurane (sold under the trademarks Ultane and Sevorane) is an anesthesia product that AbbVie sells worldwide for human
use. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48901_our_corporate_information"> </A>
<A NAME="toc_ca48901_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Our Corporate Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie was incorporated in Delaware on April&nbsp;10, 2012. On January&nbsp;1, 2013, AbbVie became an independent publicly traded company
company as a result of the distribution by Abbott Laboratories ("Abbott") of 100&nbsp;percent of the outstanding common stock of AbbVie to Abbott's shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie's
common stock began trading "regular-way" under the ticker symbol "ABBV" on the New York Stock Exchange on January&nbsp;2, 2013. AbbVie's common stock is also listed on the
Chicago Stock Exchange under the symbol "ABBV." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
maintains an Internet site at </FONT><FONT SIZE=2><I>www.abbvie.com</I></FONT><FONT SIZE=2>. AbbVie's website and the information contained therein or connected thereto shall not
be deemed to be incorporated herein, and you should not rely on any such information in making an investment decision. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
information regarding the results of AbbVie's historical operations, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" in AbbVie's
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/abbv-20181231x10k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018,</A> which is incorporated by reference into this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
is a Delaware corporation. The address of AbbVie's principal executive offices is 1 North Waukegan Road, North Chicago, Illinois 60064. AbbVie's telephone number is
(847)&nbsp;932-7900. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48901_our_acquisition_of_allergan"> </A>
<A NAME="toc_ca48901_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Our Acquisition of Allergan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allergan, an Irish public limited company, is a global pharmaceutical leader. Allergan is focused on developing, manufacturing and
commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class
products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. Allergan has operations in more than 100 countries. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=960385,FOLIO='S-10',FILE='DISK110:[19ZCG1.19ZCG48901]CA48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ca48901_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;25, 2019, AbbVie and Venice Subsidiary&nbsp;LLC ("Acquirer Sub"), a Delaware limited liability company and wholly-owned subsidiary of AbbVie, entered into a transaction
agreement (the "Transaction Agreement") with Allergan. Under the terms of the Transaction Agreement, Acquirer Sub will acquire Allergan pursuant to a scheme of arrangement under Chapter&nbsp;1 of
Part&nbsp;9 of the Irish Companies Act 2014 (the "Act") and a capital reduction under Sections&nbsp;84 to 86 of the Act (collectively referred to as the "Scheme"). As a result of the Scheme,
Allergan will become a wholly-owned subsidiary of AbbVie. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completion
of the Acquisition is subject to customary closing conditions, including, among other things, the approval of the Scheme by the Allergan shareholders, the sanction of the
Scheme by the Irish High Court (the "Court"), the registration of the order or orders of the Court sanctioning the Scheme under Section&nbsp;453 of the Act and confirming the reduction of capital
that forms part of it under Sections&nbsp;84 and 85 of the Act with the Registrar of Companies in Dublin, Ireland and the receipt of certain regulatory approvals, including the expiry or termination
of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and, to the extent applicable, any agreement between Allergan and AbbVie, on the one hand,
and the U.S. Federal Trade Commission or the Antitrust Division of the U.S. Department of Justice, on the other hand, not to consummate the Scheme or the Acquisition having expired or been earlier
terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Acquisition is expected to be completed in early 2020. There can be no assurance that we, Acquirer Sub and Allergan will be able to consummate the Acquisition on a timely basis or at
all. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=13,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=275442,FOLIO='S-11',FILE='DISK110:[19ZCG1.19ZCG48901]CA48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cc48901_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc48901_selected_historical_co__cc402261"> </A>
<A NAME="toc_cc48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF ABBVIE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth selected financial information for AbbVie as of and for the periods indicated. The selected financial information
of AbbVie as of and for the periods from 2016 to 2018 are derived from its audited consolidated financial statements as of and for the years ended December&nbsp;31, 2018, 2017 and 2016. The selected
interim financial information has been derived from AbbVie's unaudited condensed consolidated financial statements and includes, in the opinion of AbbVie's management, all normal and recurring
adjustments necessary for a fair presentation of the financial information. The results for the six-month period ended June&nbsp;30, 2019 do not necessarily indicate the results to be expected for
the full year. You should read the following information in conjunction with AbbVie's consolidated financial statements and related notes and other financial information incorporated by reference in
this prospectus supplement and the accompanying prospectus. Historical results are not necessarily indicative of any results to be expected in the future. See "Where to Obtain More Information." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of and for the<BR>
six months<BR>
ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of and for the years ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in millions)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of earnings data</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net revenues</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,753</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,216</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net earnings</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,309</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,953</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance sheet data</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,142</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61,641</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59,352</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,786</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,099</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term debt and finance lease obligations(a)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,954</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,611</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,465</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
current portion of both long-term debt and finance lease obligations.  </FONT></DD></DL>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=512615,FOLIO='S-12',FILE='DISK110:[19ZCG1.19ZCG48901]CC48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ce48901_1_13"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce48901_the_offering"> </A>
<A NAME="toc_ce48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The summary below describes the principal terms of the Notes offered hereby. Certain of the terms and conditions
described below are subject to important limitations and exceptions. You should carefully review the "Description of Notes" section of this prospectus supplement, which contains a more detailed
description of the terms and conditions of the Notes.</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Issuer</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>AbbVie&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Securities Offered</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aggregate principal amount of 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aggregate principal amount of 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Interest Rate on Notes</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Interest Payment Dates</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The Issuer will pay interest on the Notes annually on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, beginning&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Maturity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Optional Redemption</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>At any time prior to the Par Call Date (as defined herein) applicable to a series of Notes, the Issuer may redeem some or all of the Notes of such series at its option, in each case at a redemption price equal to the
greater of (1)&nbsp;100% of the principal amount of the Notes of that series to be redeemed and (2)&nbsp;the sum of the present values of the remaining scheduled payments (through the Par Call Date with respect to such Notes assuming for such purpose
that such Notes matured on the applicable Par Call Date) of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the date of redemption on an annual basis (Actual/Actual (ICMA)) at
the applicable Comparable Bond Rate (as defined herein) plus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;basis points for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;basis points for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>In each case, the Issuer will pay accrued and unpaid interest on the principal amount being redeemed to, but excluding, the date of redemption.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>In addition, at any time on or after the Par Call Date applicable to a series of Notes, the Issuer may redeem some or all of the Notes of such series at its option, in each case at a redemption price equal to 100% of
the principal amount of the Notes of that series to be redeemed, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to, but excluding, the date of redemption.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>"Par Call Date" means (i)&nbsp;with respect to the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior to the maturity date of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes) and (ii)&nbsp;with respect to the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior to the maturity date of the
20&nbsp;&nbsp;&nbsp;&nbsp;Notes).</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=813734,FOLIO='S-13',FILE='DISK110:[19ZCG1.19ZCG48901]CE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ce48901_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The redemption provisions are discussed in this prospectus supplement under "Description of Notes&#151;Optional Redemption."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Redemption for Tax Reasons</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The Issuer may redeem each series of Notes at its option in whole, but not in part, if the tax laws of the United States (or any taxing authority in the United States) change and it becomes obligated to pay additional
amounts on the Notes as described under "Description of Notes&#151;Payments of Additional Amounts." This redemption would be at 100% of the principal amount, together with accrued and unpaid interest on the Notes of such series to the date fixed for
redemption.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>See "Description of Notes&#151;Redemption for Tax Reasons."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Ranking</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The Notes will be the Issuer's unsecured, unsubordinated obligations, and will:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>rank equally in right of
payment with all of the Issuer's existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>rank senior in right of
payment to all of the Issuer's future indebtedness that is subordinated to the Notes;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>be effectively
subordinated in right of payment to all of the Issuer's existing and future secured indebtedness, to the extent of the value of the assets securing such indebtedness; and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>be structurally
subordinated in right of payment to all existing and future indebtedness, liabilities and other obligations of the Issuer's subsidiaries.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Currency of Payment</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>All payments of interest and principal, including payments made upon any redemption of the Notes, will be made in euro. If the euro is unavailable to the Issuer due to the imposition of exchange controls or other
circumstances beyond the Issuer's control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or
within the international banking community, then all payments in respect of the Notes will be made in dollars until the euro is again available to the Issuer or so used.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=904371,FOLIO='S-14',FILE='DISK110:[19ZCG1.19ZCG48901]CE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ce48901_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Additional Amounts</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The Issuer will, subject to certain exceptions and limitations set forth herein, pay additional amounts on the Notes as are necessary in order that the net payment by it of the principal of, and premium, if any, and
interest on the Notes to a holder who is not a U.S. person, after withholding or deduction for any future tax, assessment or other governmental charge imposed by the United States or a taxing authority in the United States will not be less than the
amount provided in the Notes to be then due and payable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>See "Description of Notes&#151;Payment of Additional Amounts."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Use of Proceeds</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The Issuer intends to use the net proceeds from the sale of the Notes, together with cash on hand, (i)&nbsp;to redeem, satisfy and discharge or repay at maturity all of the 2019 Notes in an aggregate outstanding
principal amount of &euro;1.4&nbsp;billion, and to pay any premium and accrued interest in respect thereof, and/or (ii)&nbsp;for general corporate purposes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Certain of the underwriters and their respective affiliates may hold positions in the 2019 Notes and, to the extent they hold such notes, they may receive a portion of the proceeds from the sale of the Notes used to
redeem, satisfy and discharge or repay at maturity such notes, as applicable. See "Use of Proceeds" and "Underwriting."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Certain Covenants</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The indenture governing the Notes includes covenants that, among other things, limit the ability of the Issuer and its subsidiaries to create or permit to exist mortgages with respect to their principal domestic
properties and certain other assets and to enter into sale and leaseback transactions with respect to principal domestic properties and limit the Issuer's ability to consolidate with or merge into any other entity or convey, transfer, or lease the
Issuer's properties and assets substantially as an entirety. These covenants are subject to a number of important qualifications and limitations. See "Description of Notes&#151;Certain Covenants of AbbVie" and "Description of Notes&#151;Consolidation,
 Merger and Sale of Assets."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Additional Notes</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The Issuer may "re-open" each series of Notes and issue an unlimited principal amount of additional Notes of that series in the future without the consent of the holders.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=720789,FOLIO='S-15',FILE='DISK110:[19ZCG1.19ZCG48901]CE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_ce48901_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Form and Denominations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The Notes will be issued in the form of Global Notes fully registered in the name of a nominee of, and deposited with, a common depositary for Euroclear and Clearstream, Luxembourg. Except in the limited circumstances
described in this prospectus supplement, owners of beneficial interests in the Notes will not be entitled to have Notes registered in their names, will not receive or be entitled to receive Notes in definitive form ("Definitive Notes") and will not
be considered holders of Notes for any purpose. The Notes will be issued in minimum denominations of &euro;100,000 and integral multiples of &euro;1,000 in excess thereof.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Risk Factors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>You should carefully consider the information set forth herein under "Risk Factors" and the other information in this prospectus supplement and the documents incorporated herein by reference in deciding whether to
purchase the Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Listing</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We intend to apply for listing the Notes for trading on the New York Stock Exchange. The listing application will be subject to approval by the New York Stock Exchange. If such a listing is obtained, we have no
obligation to maintain such listing, and we may delist the Notes at any time.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Material U.S. Federal Income Tax Considerations</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>See "Material U.S. Federal Income Tax Considerations."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Selling Restrictions</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>You should carefully read and consider the information set forth in "Notice to Residents of the United Kingdom," "Notice to Residents of the European Economic Area" and "Underwriting&#151;Selling Restrictions" before
investing in the Notes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Trustee</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>U.S. Bank National Association.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>London Paying Agent</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Elavon Financial Services DAC, UK Branch</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Registrar and Transfer Agent</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Elavon Financial Services DAC</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Governing Law</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The State of New York.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=930513,FOLIO='S-16',FILE='DISK110:[19ZCG1.19ZCG48901]CE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da48901_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da48901_risk_factors"> </A>
<A NAME="toc_da48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should carefully consider the following risk factors, as well as the other information included or incorporated by
reference into this prospectus supplement and the accompanying prospectus, before making an investment decision. These risks are not the only risks that we face in our business and/or in connection
with this offering. Our business, financial condition and results of operations and/or the Notes offered hereby could also be affected by additional factors that are not presently known to us or that
we currently do not consider to be material.</I></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Relating to Our Business  </I></B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The proposed Acquisition may not be completed on the currently contemplated timeline or terms, or at all, and
may not achieve the intended benefits.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consummation of the Acquisition is conditioned on, among other things, obtaining necessary governmental, regulatory and Allergan shareholder
approvals. If any of the conditions to the Acquisition is not satisfied, it could delay or prevent the proposed Acquisition from occurring, which could negatively impact the Issuer's share price and
future business and financial results. Further, as a condition to their approval of the Acquisition, agencies may impose requirements, limitations or costs or require divestitures or place
restrictions on the conduct of the Issuer's business after the closing. These requirements, limitations, costs, divestitures or restrictions could jeopardize or delay the consummation of the
Acquisition or may reduce the anticipated benefits of the transaction. The Issuer will incur increased indebtedness to fund the cash consideration for the Acquisition and such indebtedness could
adversely affect the Issuer's business, financial condition, or results of operations. Following the proposed Acquisition, the Issuer may not realize the proposed Acquisition's intended benefits
within the expected timeframe or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
a discussion of other risks related to our business you should carefully consider the risks, uncertainties and assumptions discussed under "Part&nbsp;I&#151;Item&nbsp;1A.
Risk Factors" in the Issuer's <A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/abbv-20181231x10k.htm">Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2018</A> and in other documents that we subsequently file with the SEC that update, supplement or supersede such information, all of which are incorporated by reference
into this prospectus supplement. See "Where to Obtain More Information." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to this Offering  </I></B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In addition to indebtedness that will be issued in this offering, the Issuer has significant outstanding
unused borrowing capacity and significant outstanding debt and may incur additional debt in the future. The terms of such indebtedness could restrict the activities of the Issuer and its subsidiaries.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2018, the Issuer entered into a $3&nbsp;billion revolving credit facility with various financial institutions, which was amended and
restated in August 2019 to increase the commitments thereunder to $4&nbsp;billion (as amended and restated, the "Revolving Credit Facility"). There are currently no amounts outstanding under the
Revolving Credit Facility. In addition, in connection with the Acquisition, the Issuer, together with various financial institutions, entered into a $38&nbsp;billion bridge credit facility (the
"Acquisition Bridge Facility") in June 2019 and a $6&nbsp;billion term loan facility (the "Acquisition Term Loan") in July 2019 (which reduced the Acquisition Bridge Facility by a like amount).
There are currently no amounts outstanding under these facilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
credit facilities impose restrictions on the Issuer and its subsidiaries, including certain restrictions on their ability to incur liens on their assets. In addition, these credit
facilities require the Issuer to maintain compliance with a financial covenant. The Issuer's ability to comply with these restrictions and covenants may be affected by events beyond its control. If
the Issuer breaches any of these restrictions or covenants and does not obtain a waiver from the lenders under the applicable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=75296,FOLIO='S-17',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_da48901_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>credit
facility, then, subject to applicable cure periods, any outstanding indebtedness under such credit facility could be declared immediately due and payable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as of June&nbsp;30, 2019, the Issuer had $37.3&nbsp;billion aggregate principal amount of unsecured senior notes outstanding (based on exchange rates in effect as of
June&nbsp;28, 2019). Prior to the closing of the Acquisition, we anticipate accessing the debt capital markets and issuing notes to fund a portion of the cash consideration that will be owed to
Allergan shareholders. The Acquisition Bridge Facility will be decreased by the proceeds of any such financing. We also intend to assume or replace Allergan's indebtedness in connection with the
closing of the Acquisition. AbbVie may also incur significantly more debt in the future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Issuer has limited direct operations and depends on dividends and other distributions from its
subsidiaries.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer has limited direct operations. The Issuer's principal assets are the equity interests that the Issuer holds in its subsidiaries. As a
result, the Issuer depends on dividends and other distributions from its subsidiaries to generate the funds necessary to meet its financial obligations, including the payment of principal and interest
on its outstanding indebtedness. The Issuer's subsidiaries are legally distinct from the Issuer and have no obligation to pay amounts due on the Issuer's indebtedness or to make funds available for
such payment. In addition, the Issuer's subsidiaries will be permitted under the terms of the indenture governing the Notes to incur additional indebtedness that may restrict or prohibit the making of
distributions, the payment of dividends or the making of loans by such subsidiaries to the Issuer. The Issuer cannot assure you that the agreements governing the current and future indebtedness of its
subsidiaries will permit such subsidiaries to provide it with sufficient dividends, distributions or loans to fund payments on the Notes when due. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An increase in interest rates could result in a decrease in the market values of the Notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, as market interest rates rise, notes bearing interest at a fixed rate decline in value because the premium over market interest
rates, if any, will decline. Consequently, if you purchase the Notes and market interest rates increase, the market values of your Notes may decline. The Issuer cannot predict the future level of
market interest rates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in the Issuer's credit ratings may adversely affect the values of the Notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any ratings assigned to the Notes could be lowered, suspended or withdrawn entirely by the rating agencies if, in each rating agency's judgment,
circumstances warrant. Following the announcement of the Acquisition, Moody's affirmed the Issuer's credit ratings, whereas S&amp;P Global Ratings placed the Issuer's credit ratings on credit watch with
negative implications. Actual or anticipated changes or downgrades in the Issuer's credit ratings, including any announcement that the Issuer's ratings are under further review for a downgrade, could
affect the market values of the Notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The indenture governing the Notes will not restrict the amount of additional debt that the Issuer and its
subsidiaries may incur.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes and the indenture under which the Notes will be issued do not place any limitation on the amount of debt that the Issuer and its
subsidiaries may incur (other than certain limited restrictions on the incurrence of certain secured debt). The Issuer's incurrence of additional debt may have important consequences for you as a
holder of the Notes, including making it more difficult for the Issuer to satisfy its obligations with respect to the Notes, a loss in the market values of the Notes and a risk that any credit rating
of the Notes is lowered or withdrawn. In addition, the Issuer is not restricted under the indenture governing the Notes from paying dividends or issuing or repurchasing its securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=648634,FOLIO='S-18',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_da48901_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no financial covenants in the indenture governing the Notes. Except for the covenants described under "Description of Notes&#151;Certain Covenants of AbbVie" and
"Description of Notes&#151;Consolidation, Merger and Sale of Assets," there are no covenants or any other provisions in the indenture under which the Notes will be issued which may afford you
protection in the event of a highly leveraged transaction, including one that may or may not result in a change of control of the Issuer. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There are currently no markets for the Notes, and active trading markets may not develop for the Notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes are new issues of securities with no established trading markets. We intend to apply for listing of the Notes for trading on the New
York Stock Exchange. The listing application will be subject to approval by the New York Stock Exchange. If such a listing is obtained, we have no obligation to maintain such listing, and we may
delist the Notes at any time. In addition, although the underwriters have advised the Issuer that they intend to make a market for each series of the Notes as permitted by applicable laws and
regulations, they have no obligation to do so and they may discontinue their market-making activities at any time without notice. In addition, the liquidity of the trading markets in the Notes and the
market prices quoted for the Notes may be adversely affected by changes in the overall market for securities and by changes in AbbVie's financial performance or prospects or changes in the financial
performance or prospects of companies in AbbVie's industry. Active trading markets for the Notes may not develop or be sustained and there can be no assurance as to the liquidity of any markets that
do develop. You may not be able to sell your Notes at a particular time, and the price that you receive when you sell may not be favorable. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Neither the Issuer nor any of its subsidiaries has any property that has been determined to be a principal
domestic property under the indenture governing the Notes. In addition, the Issuer's board of directors has broad discretion to determine that a property is not a principal domestic property and
therefore not subject to certain covenants in the indenture governing the Notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture governing the Notes includes covenants that, among other things, limit the ability of the Issuer and its subsidiaries to create or
permit to exist mortgages with respect to their principal domestic properties and certain other assets and to enter into sale and leaseback transactions with respect to such principal domestic
properties. However, as of the date of this prospectus supplement, neither the Issuer, nor any of its subsidiaries, has any property that constitutes a principal domestic property under the indenture
governing the Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the indenture governing the Notes provides that a principal domestic property means any building, structure or other facility, together with the land on which it is erected
and fixtures comprising a part thereof, used primarily for manufacturing, processing, research, warehousing or distribution and located in the United States (excluding its territories and possessions
and Puerto Rico), owned or leased by the Issuer or any of its domestic subsidiaries and having a net book value which, on the date the determination as to whether a property is a principal domestic
property is being made, exceeds 2% of the consolidated net assets of the Issuer, other than any such building, structure or other facility or a portion thereof (i)&nbsp;which is an air or water
pollution control facility financed by state or local governmental obligations or (ii)&nbsp;which the chairman of the board, chief executive officer, an executive vice president, a senior vice
president or a vice president and the chief financial officer, treasurer, or assistant treasurer of the Issuer determine in good faith, at any time on or prior to such date, is not of material
importance to the total business conducted, or assets owned, by the Issuer and its subsidiaries as an entirety. Although it has not yet done so, under the terms of the indenture governing the Notes,
the chairman of the board of the Issuer or any of the Issuer's executive officers listed above may determine from time to time that a property owned by the Issuer or its subsidiaries is not a
principal domestic property and therefore such property is not subject to the covenants in the indenture governing the Notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=962051,FOLIO='S-19',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_da48901_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Notes will not be guaranteed by any of the Issuer's subsidiaries and are structurally subordinated to any
existing or future preferred stock, indebtedness, guarantees and other liabilities of the Issuer's subsidiaries.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes will be obligations exclusively of the Issuer and will not be guaranteed by any of the Issuer's subsidiaries. As a result, the Notes
will be structurally subordinated to existing or future preferred stock, indebtedness, guarantees and other liabilities, including trade payables, of the Issuer's subsidiaries. The indenture governing
the Notes does not restrict the Issuer or its subsidiaries from incurring substantial additional indebtedness in the future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June&nbsp;30, 2019, on an as adjusted basis, giving effect to the issuance and sale of the Notes and the application of the estimated net proceeds therefrom, as described in this
prospectus supplement, as if such transaction had occurred on June&nbsp;30, 2019, the Issuer would have had approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;billion of outstanding indebtedness. In addition,
the Issuer has unused borrowing capacity of up to (i)&nbsp;$4&nbsp;billion under the Revolving Credit Facility, (ii)&nbsp;$32&nbsp;billion under the Acquisition Bridge Facility and
(iii)&nbsp;$6&nbsp;billion under the Acquisition Term Loan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Issuer's subsidiaries are separate and distinct legal entities from the Issuer and such subsidiaries have no obligation to pay any amounts due on the Notes or to provide the Issuer
with funds to meet the payment obligations on the Notes. Any payment of dividends, loans or advances by the Issuer's subsidiaries could be subject to statutory or contractual restrictions and will be
contingent upon the subsidiaries' earnings and business considerations. The Issuer's right to receive any assets of any of its subsidiaries upon their bankruptcy, liquidation, or similar
reorganization, and the rights of the holders of the Notes, will be structurally subordinated to all existing and future indebtedness and other liabilities of such subsidiaries. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Notes are subject to prior claims of secured creditors.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes will be unsecured, unsubordinated obligations of the Issuer, and will rank equally in right of payment with all of the Issuer's
existing and future unsecured senior indebtedness, liabilities and other obligations and will be effectively subordinated to all of the Issuer's existing and future secured indebtedness to the extent
of the value of the assets securing such indebtedness. As of June&nbsp;30, 2019, the Issuer did not have any significant secured debt outstanding. However, each of the indenture governing the Notes
and the agreements governing the Issuer's credit facilities permits the Issuer and its subsidiaries to incur secured debt under certain circumstances, and the amounts could be substantial. If the
Issuer incurs any debt secured by its assets or the assets of its subsidiaries, these assets could be subject to the claims of secured creditors that are prior to your claim as a holder of Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a bankruptcy, liquidation, or similar proceeding, the pledged assets of the Issuer would be available to satisfy obligations in respect of the secured debt before any
payment could be made on the Notes. As a result, the Notes will be effectively subordinated to any secured debt that the Issuer may have to the extent of the value of the assets securing such debt. To
the extent that such pledged assets cannot satisfy such secured debt, the holders of such debt would have a claim for any shortfall that would rank equally in right of payment with the Notes. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Issuer's credit ratings may not reflect all risks of your investment in the Notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any credit ratings assigned or that will be assigned to the Notes are limited in scope, and do not address all material risks relating to an
investment in the Notes, but rather reflect only the view of each rating agency at the time the rating is issued. An explanation of the significance of such rating may be obtained from such rating
agency. There can be no assurance that such credit ratings will remain in effect for any given period of time or that a rating will not be lowered, suspended or withdrawn entirely by the applicable
rating agencies, if, in such rating agency's judgment, circumstances so warrant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=426049,FOLIO='S-20',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_da48901_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agency
credit ratings are not a recommendation to buy, sell or hold any security. Each agency's rating should be evaluated independently of any other agency's rating. Actual or
anticipated changes or downgrades in the Issuer's credit ratings, including any announcement that its ratings are under further review for a downgrade, could affect the market values of the Notes and
increase the Issuer's corporate borrowing costs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Issuer may choose to redeem the Notes of any series prior to maturity.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Issuer may redeem some or all of the Notes of any series at any time. See "Description of Notes&#151;Optional Redemption." Although
the Notes contain provisions designed to compensate you for the lost value of your Notes if the Issuer redeems some or all of the Notes prior to maturity, they are only an approximation of this lost
value and may not adequately compensate you. Furthermore, depending on prevailing interest rates at the time of any such redemption, you may not be able to reinvest the redemption proceeds in a
comparable security at an interest rate as high as the interest rate of the Notes being redeemed or at an interest rate that would otherwise compensate you for any lost value as a result of any
redemption of Notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An investment in the Notes by a holder whose home currency is not euro entails significant risks.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All payments of interest on and the principal of the Notes and any redemption price for the Notes will be made in euro. An investment in the
Notes by a holder whose home currency is not euro entails significant risks. These risks include the possibility of significant changes in rates of exchange between the holder's home currency and euro
and the possibility of the imposition or subsequent modification of foreign exchange controls. These risks generally depend on factors over which the Issuer has no control, such as economic, financial
and political events and the supply of and demand for the relevant currencies. In the past, rates of exchange between euro and certain currencies have been highly volatile, and each holder should be
aware that volatility may occur in the future. Fluctuations in any particular exchange rate that have occurred in the past, however, are not necessarily indicative of fluctuations in the rate that may
occur during the term of the Notes. Depreciation of euro against the holder's home currency would result in a decrease in the effective yield of the Notes below its coupon rate and, in certain
circumstances, could result in a loss to the holder. If you are a holder subject to U.S. income tax, see "Material U.S. Federal Income Tax Considerations" for the material U.S. federal income tax
consequences of the acquisition, ownership and disposition of the Notes related to the Notes being denominated in euro. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Notes permit the Issuer to make payments in dollars if the Issuer is unable to obtain euro.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the euro is unavailable to the Issuer due to the imposition of exchange controls or other circumstances beyond the Issuer's control or if the
euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or
within the international banking community, then all payments in respect of the Notes will be made in dollars until the euro is again available to the Issuer or so used. The amount payable on any date
in euro will be converted into dollars on the basis of the market exchange rate for euro most recently available on, or prior to, the second business day before the relevant payment date. Any payment
in respect of the Notes so made in dollars will not constitute an event of default under the Notes or the indenture governing the Notes. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In a lawsuit for payment on the Notes, an investor may bear currency exchange risk.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture is, and the Notes will be, governed by the laws of the State of New York. Under New York law, a New York state court rendering a
judgment on the Notes would be required to render the judgment in euro. However, the judgment would be converted into dollars at the
exchange rate prevailing on the date of entry of the judgment. Consequently, in a lawsuit for payment on the Notes, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=23,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=694498,FOLIO='S-21',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_da48901_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>investors
would bear currency exchange risk until a New York state court judgment is entered, which could be a significant amount of time. A federal court sitting in New York with diversity
jurisdiction over a dispute arising in connection with the Notes would apply New York law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
courts outside of New York, investors may not be able to obtain a judgment in a currency other than dollars. For example, a judgment for money in an action based on the Notes in many
other U.S. federal or state courts ordinarily would be enforced in the United States only in dollars. The date used to determine the rate of conversion of euro into dollars would depend upon various
factors, including which court renders the judgment and when the judgment is rendered. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Trading in the clearing systems is subject to minimum denomination requirements.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms of the Notes provide that Notes will be issued with a minimum denomination of &euro;100,000 and multiples of
&euro;1,000 in excess thereof. It is possible that the clearing systems may process trades that could result in amounts being held in denominations smaller than the minimum denominations.
If Definitive Notes are required to be issued in relation to such Notes in accordance with the provisions of the relevant Global Notes, a holder who does not have the minimum denomination or a
multiple of &euro;1,000 in excess thereof in its account with the relevant clearing system at the relevant time may not receive all of its entitlement in Definitive Notes unless and until
such time as its holding satisfies the minimum denomination requirement. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As Global Notes are held by or on behalf of Euroclear and Clearstream, Luxembourg, investors will have to
rely on their procedures for transfer, payment and communication with the Issuer.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes will be represented by Global Notes except in certain limited circumstances described in the Global Notes. The Notes will be deposited
with a common depositary for Euroclear and Clearstream, Luxembourg. Except in certain limited circumstances described in the Global Notes, investors will not be entitled to receive Definitive Notes.
Euroclear and Clearstream,
Luxembourg will maintain records of the beneficial interests in the Global Notes and, while the Notes are in global form, investors will be able to trade their beneficial interests only through
Euroclear and Clearstream, Luxembourg. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
the Notes are represented by Global Notes, the Issuer will discharge its payment obligations under the Notes by making payments to or to the order of a nominee for a common
depositary for Euroclear and Clearstream, Luxembourg for distribution to their accountholders. A holder of a beneficial interest in a Global Note must rely on the procedures of Euroclear and
Clearstream, Luxembourg to receive payments under the Notes. The Issuer has no responsibility or liability for the records relating to, or payments made in respect of, beneficial interests in a Global
Note. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The United Kingdom's impending departure from the European Union could adversely affect the value of the
Notes.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The United Kingdom held a referendum on June&nbsp;23, 2016 in which a majority of voters voted to exit the European Union ("Brexit") and on
March&nbsp;29, 2017, the United Kingdom submitted a formal notification of its intention to withdraw from the European Union pursuant to Article&nbsp;50 of the Treaty of Lisbon. The deadline for
the United Kingdom to negotiate the terms of its withdrawal from, and future relationship with, the European Union, including the terms of trade between the United Kingdom and the European Union and
potentially other countries, was recently extended to October&nbsp;31, 2019, and the suspension or further delay of such deadline requires the unanimous agreement of all remaining member states. If
no formal withdrawal agreement is reached between the United Kingdom and the European Union by the October&nbsp;31, 2019 deadline, then it is expected that the United Kingdom's membership in the
European Union will automatically terminate on such date. Discussions between the United Kingdom and the European Union focused on finalizing withdrawal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=24,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=498676,FOLIO='S-22',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_da48901_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>issues
and transition agreements are ongoing. However, limited progress to date in these negotiations and ongoing uncertainty within the UK Government and Parliament sustains the possibility of the
United Kingdom leaving the European Union on October&nbsp;31, 2019 without a withdrawal agreement and associated transition period in place, which is likely to cause significant market and economic
disruption. The effects of Brexit will depend on any agreements the United Kingdom makes to retain access to European Union markets either during a transitional period or more permanently. Brexit
could adversely affect European and worldwide economic and market conditions and could contribute to instability in global financial and foreign exchange markets, including volatility in the value of
the euro. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the United Kingdom determines which European Union laws to replace or
replicate. Any
of these effects of Brexit, and others the Issuer cannot anticipate, could negatively impact the value of the Notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=25,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=267508,FOLIO='S-23',FILE='DISK110:[19ZCG1.19ZCG48901]DA48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc48901_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc48901_use_of_proceeds"> </A>
<A NAME="toc_dc48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect the net proceeds to us from this offering will be approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;billion (or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;billion
using the noon buying rate in New York City on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 for cable transfers
of&nbsp;&euro;1.00=$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as announced by the U.S. Federal Reserve Board for euro),
after deducting underwriting discounts and our estimated offering expenses. We intend to use the net proceeds from the sale of the Notes, together with cash on hand, (i)&nbsp;to redeem, satisfy and
discharge or repay at maturity all of the 2019 Notes in an aggregate outstanding principal amount of &euro;1.4&nbsp;billion, and to pay any premium and accrued interest in respect
thereof, and/or (ii)&nbsp;for general corporate purposes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
of the underwriters and their respective affiliates may hold positions in the 2019 Notes and, to the extent they hold such notes, they may receive a portion of the proceeds from
the sale of the Notes used to redeem, satisfy and discharge or repay at maturity such notes, as applicable. See "Underwriting&#151;Other Relationships." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=26,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=542518,FOLIO='S-24',FILE='DISK110:[19ZCG1.19ZCG48901]DC48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dc48901_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc48901_currency_conversion"> </A>
<A NAME="toc_dc48901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CURRENCY CONVERSION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal and interest payments in respect of the Notes and any redemption price for the Notes will be payable in euro. If the euro is
unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Monetary Union
that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the Notes
will be made in dollars until the euro is again available to us or so used. The amount payable on any date in euro will be converted into dollars on the basis of the market exchange rate for euro most
recently available on, or prior to, the second business day before the relevant payment date. Any payment in respect of the Notes so made in dollars will not constitute an event of default under the
Notes or the indenture governing the Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investors
will be subject to foreign exchange risks as to payments of principal and interest that may have important economic and tax consequences to them. See "Risk Factors." You should
consult your own financial and legal advisors as to the risks involved in an investment in the Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019, the noon buying rate in New York City for cable transfers as announced by the U.S. Federal Reserve Board was &euro;1.00=$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=27,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=430758,FOLIO='S-25',FILE='DISK110:[19ZCG1.19ZCG48901]DC48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dc48901_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc48901_capitalization"> </A>
<A NAME="toc_dc48901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our capitalization as of June&nbsp;30, 2019 on an actual and as adjusted basis to give effect to the issuance
and sale of the Notes and the application of the estimated net proceeds therefrom, as described in this prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actual
amounts set forth in the table are subject to adjustments and may differ at the time of the consummation of the proposed transactions depending on several factors, including
changes in the actual amount of fees and expenses related to the proposed transactions and the outstanding amount of indebtedness at that time. The table below does not reflect any changes that may
result at the closing of the Acquisition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this table in conjunction with the "Use of Proceeds" section and the consolidated financial statements and accompanying notes thereto and other financial information,
which are incorporated by reference into this prospectus supplement. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of June&nbsp;30, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As Adjusted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(rounded to dollars in millions)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,172</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total debt and finance lease obligations:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revolving Credit Facility (up to $3&nbsp;billion)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Acquisition Bridge Facility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>0.38% notes due 2019 (&euro;1,400 principal)(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,590</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.50% notes due 2020(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.30% notes due 2021(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,799</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,799</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.375% notes due 2021(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.90% notes due 2022(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,093</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.20% notes due 2022(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.85% notes due 2023(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.75% notes due 2023(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1.38% notes due 2024 (&euro;1,450 principal)(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.60% notes due 2025(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,746</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,746</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3.20% notes due 2026(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2.13% notes due 2028 (&euro;750 principal)(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.25% notes due 2028(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.50% notes due 2035(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.30% notes due 2036(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.40% notes due 2042(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,579</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,579</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.70% notes due 2045(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,699</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,699</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.45% notes due 2046(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4.875% notes due 2048(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes offered hereby:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>20&nbsp;&nbsp;&nbsp;&nbsp;% senior notes due 20&nbsp;&nbsp;&nbsp;&nbsp;(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>20&nbsp;&nbsp;&nbsp;&nbsp;% senior notes due 20&nbsp;&nbsp;&nbsp;&nbsp;(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>337</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>337</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value hedges</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unamortized deferred financing costs(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(321</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(321</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,526</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Net
of discount.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
on a U.S. dollar to euro exchange rate of 0.8793 as of June&nbsp;28, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Excludes
the impact of the Notes offered hereby.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=28,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=56100,FOLIO='S-26',FILE='DISK110:[19ZCG1.19ZCG48901]DC48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dc48901_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc48901_description_of_notes"> </A>
<A NAME="toc_dc48901_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF NOTES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes will be issued under an indenture, dated as of November&nbsp;8, 2012 (the "indenture"), between AbbVie and U.S. Bank National
Association, as trustee (the "Trustee"), as supplemented by one or more supplemental indentures relating to the Notes. The following description of the terms of the Notes supplements, and, to the
extent it is inconsistent therewith replaces, the description of the general terms of debt securities set forth in the accompanying prospectus, to which description reference is hereby made. The
following summary of certain provisions of the indenture and the Notes does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all the provisions of the
indenture and the Notes, including the definitions of certain terms therein and those terms made part thereof by the Trust Indenture Act of 1939, as amended (the "Trust Indenture Act"). In this
description all references to "AbbVie," "we," "our" and "us" mean AbbVie&nbsp;Inc. only. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie is issuing &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aggregate principal amount of 20&nbsp;&nbsp;&nbsp;&nbsp;Notes. The
20&nbsp;&nbsp;&nbsp;&nbsp;Notes will mature
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;. Interest on the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes will accrue at the rate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% per annum. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
is issuing &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aggregate principal amount of 20&nbsp;&nbsp;&nbsp;&nbsp;Notes. The 20&nbsp;&nbsp;&nbsp;&nbsp;Notes will mature
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;.
Interest on the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes will accrue at the rate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% per annum. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Notes will be issued in fully registered form only in denominations of &euro;100,000 and integral multiples of &euro;1,000 in excess thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the future, AbbVie may, without the consent of the holders, increase the principal amounts of any series of Notes offered hereby. The Notes of each series and any additional Notes of
such series subsequently issued under the indenture will be treated as a single series or class for all purposes under the indenture, including, without limitation, waivers, amendments and
redemptions, provided that if any such additional Notes are not fungible with the existing Notes for United States federal income tax purposes, such additional Notes will have a separate CUSIP number. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
indenture limits neither the amount of debt that AbbVie may issue under the indenture, nor the amount of other debt or securities that AbbVie or any of its subsidiaries may issue.
AbbVie may issue debt securities under the indenture from time to time in one or more series, each in an amount authorized prior to issuance. Other than the restrictions contained in the indenture on
secured debt and sale/leaseback transactions described below under "Certain Covenants of AbbVie," and the restrictions described below under "Consolidation, Merger and Sale of Assets," the indenture
does not contain any covenants or other provisions designed to protect holders of the debt securities in the event AbbVie participates in a highly leveraged transaction. In addition, the indenture
does not limit AbbVie's ability to guarantee any indebtedness of its subsidiaries or any other person. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest on each series of Notes will be payable in arrears on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of each year, beginning
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, to the persons
in whose names the Notes are registered at the close of business on the date that is (i)&nbsp;in the case of Notes represented by a Global Note, the clearing system business day (which, for these
purposes, is a day on which Euroclear and Clearstream, Luxembourg settle payments in euro) immediately prior to the relevant interest payment date and (ii)&nbsp;in all other cases, 15 calendar days
prior to the relevant interest payment date (whether or not a business day) (such day, the "Record Date"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
on the Notes shall be determined on the basis of the actual number of days in the period for which interest is being calculated, and including the last date on which interest
was paid or duly provided for on the Notes (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, if no interest has been paid on the Notes), but excluding </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=29,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=511762,FOLIO='S-27',FILE='DISK110:[19ZCG1.19ZCG48901]DC48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dc48901_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
next following interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, the term "business day" means any day, other than a Saturday or Sunday, (i)&nbsp;which is not a day on which banking institutions in The City of New York or
London are authorized or required by law or executive order to close and (ii)&nbsp;on which the Trans-European Automated Realtime Gross Settlement Express Transfer system, or the TARGET2 system, or
any successor thereto, operates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Optional Redemption  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At any time prior to the Par Call Date applicable to a series of Notes, AbbVie may redeem some or all of the Notes of such series at its option,
in each case, at AbbVie's option, at a redemption price equal to the greater of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 100% of the principal amount of the Notes of that series to be redeemed; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sum of the present values of the remaining scheduled payments (through the Par Call Date with respect to such Notes assuming for such
purpose that such Notes matured on the applicable Par Call Date) of principal and interest on the Notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the date
of redemption on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Bond Rate (as defined below) plus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;basis points for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
basis points for the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
each case, AbbVie will pay accrued and unpaid interest on the principal amount being redeemed to, but excluding, the date of redemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, at any time on or after the Par Call Date applicable to a series of Notes, AbbVie may redeem some or all of the Notes of such series, at its option, in each case at a
redemption price equal to 100% of the principal amount of the Notes of that series to be redeemed, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to, but
excluding, the date of redemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the foregoing discussion of optional redemption, the following definitions are applicable: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Comparable
Government Bond" means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a bond that is a
direct obligation of the Federal Republic of Germany ("German government bond"), whose maturity is closest to the maturity of the notes, or if such independent investment bank in its discretion
determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and/or market makers in, German
government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Comparable
Government Bond Rate" means the yield to maturity, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), on the third business day
prior to the date fixed for redemption, of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00&nbsp;a.m.
(London time) on such business day as determined by an independent investment bank selected by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Par
Call Date" means (i)&nbsp;with respect to the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior to the maturity date of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes)
and (ii)&nbsp;with respect to the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prior to the maturity date of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=30,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=161511,FOLIO='S-28',FILE='DISK110:[19ZCG1.19ZCG48901]DC48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de48901_1_29"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice of redemption will be mailed at least 30 but not more than 60&nbsp;days before the redemption date (i)&nbsp;in the case of Notes represented by a
Global Note, to and through Euroclear or Clearstream, Luxembourg for communication by them to the holders of interests in the Notes, or (ii)&nbsp;in the case of Definitive Notes, to each holder of
record of the Notes to be redeemed at its registered address. The notice of redemption for the Notes will state, among other things, the series and amount of Notes to be redeemed, the redemption date,
the redemption price and the place or places that payment will be made upon presentation and surrender of Notes to be redeemed. Unless AbbVie defaults in the payment of the redemption price, interest
will cease to accrue on any Notes that have been called for redemption at the redemption date. If fewer than all of the Notes of a series are to be redeemed at any time, (i)&nbsp;in the case of
Notes represented by a Global Note, the Notes will be selected in accordance with the rules of Euroclear and/or Clearstream, Luxembourg (to be reflected in the records of Euroclear and Clearstream,
Luxembourg as either a pool factor or a reduction in nominal amount, at their discretion), or (ii)&nbsp;in the case of Definitive Notes, the Trustee will select, not more than 45&nbsp;days prior
to the redemption date, the particular Notes or portions thereof for redemption from the outstanding Notes not previously redeemed by random lot. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment of Additional Amounts  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie will, subject to the exceptions and limitations set forth below, pay as additional interest on each series of the Notes such additional
amounts as are necessary in order that the net amount of the principal of, and premium, if any, and interest on such Notes received by a beneficial owner who is not a U.S. person (as defined below),
after withholding or deduction for any future tax, assessment or other governmental charge imposed by the United States or a taxing authority in the United States, will not be less than the amount
provided in the Notes to be then due and payable; provided, however, that the foregoing obligation to pay additional amounts shall not apply: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge that would not have been imposed but for the holder (or the beneficial owner for whose benefit such holder holds
such Note), or a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust
administered by a fiduciary holder, being considered as:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>being
or having been engaged in a trade or business in the United States or having or having had a permanent establishment in the United States;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>having
a current or former connection with the United States (other than a connection arising solely as a result of the ownership of the Notes or the receipt of any
payment or the enforcement of any rights thereunder), including being or having been a citizen or resident of the United States;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>being
or having been a personal holding company, a passive foreign investment company or a controlled foreign corporation for U.S. federal income tax purposes or a
corporation that has accumulated earnings to avoid U.S. federal income tax;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>being
or having been a "10-percent shareholder" of the Company as defined in section&nbsp;871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the
"Code"), or any successor provision; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>being
a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business;
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any holder that is not the sole beneficial owner of the Notes, or a portion of the Notes, or that is a fiduciary, partnership or limited liability company, but
only to the extent that a beneficial owner with respect to the holder, a beneficiary or settlor with respect to the fiduciary, or a beneficial owner or member of the partnership or limited liability
company </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=627094,FOLIO='S-29',FILE='DISK110:[19ZCG1.19ZCG48901]DE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_de48901_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>would
not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge that would not have been imposed but for the failure of the holder or beneficial owner or any other person to
comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner
of the Notes, if compliance is required by statute, by regulation of the United States or any taxing authority therein or by an applicable income tax treaty to which the United States is a party as a
precondition to exemption from such tax, assessment or other governmental charge;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge that is imposed otherwise than by withholding by AbbVie or a paying agent from the payment;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge that would not have been imposed but for a change in law, regulation, or administrative or judicial
interpretation that becomes effective more than 15&nbsp;days after the payment becomes due or is duly provided for, whichever occurs later;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any estate, inheritance, gift, sales, excise, transfer, wealth, capital gains or personal property tax or similar tax, assessment or other governmental charge;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge required to be withheld by any paying agent from any payment of principal of or interest on any Note, if such
payment can be made without such withholding by at least one other paying agent;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge that would not have been imposed but for the presentation by the holder of any Note, where presentation is
required, for payment on a date more than 30&nbsp;days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge that would not have been imposed or withheld but for the beneficial owner being a bank (i)&nbsp;purchasing the
Notes in the ordinary course of its lending business or (ii)&nbsp;that is neither (A)&nbsp;buying the Notes for investment purposes only nor (B)&nbsp;buying the Notes for resale to a third-party
that either is not a bank or holding the Notes for investment purposes only;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any tax, assessment or other governmental charge imposed under Sections&nbsp;1471 through 1474 of the Code (or any amended or successor provisions), any
current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section&nbsp;1471(b) of the Code, any intergovernmental agreement entered into in connection
with the implementation of such sections of the Code or any fiscal or regulatory legislation, rules or practices adopted pursuant to any such intergovernmental agreement; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
the case of any combination of items&nbsp;(1), (2), (3), (4), (5), (6), (7), (8), (9)&nbsp;and (10). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Notes are subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable to the Notes. Except as specifically provided
under this heading "&#151;Payment of Additional Amounts," AbbVie will not be required to make any payment for any tax, assessment or other governmental charge imposed by any government or a
political subdivision or taxing authority of or in any government or political subdivision. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used under this heading "&#151;Payment of Additional Amounts" and under the heading "&#151;Redemption for Tax Reasons", the term "United States" means the United States
of America, the states of the United States, and the District of Columbia, and the term "U.S. person" means any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=32,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=925036,FOLIO='S-30',FILE='DISK110:[19ZCG1.19ZCG48901]DE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_de48901_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>individual
who is a citizen or resident of the United States for U.S. federal income tax purposes, a corporation, partnership or other entity created or organized in or under the laws of the United
States, any state of the United States or the District of Columbia, or any estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption for Tax Reasons  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or
any taxing authority in the United States), or any change in, or amendment to, an official position or judicial precedent regarding the application or interpretation of such laws, regulations or
rulings, which change or amendment is announced or becomes effective on or after the date of this prospectus supplement, AbbVie becomes or, based upon a written opinion of independent counsel selected
by it, will become obligated to pay additional amounts as described under the heading "&#151;Payment of Additional Amounts" with respect a series of Notes, then AbbVie may at any time at its
option redeem, in whole, but not in part, the Notes of such series on not less than 30 nor more than 60&nbsp;days' prior notice, (i)&nbsp;in the case of Notes represented by a Global Note, to and
through Euroclear or Clearstream, Luxembourg for communication by them to the holders of interests in the Notes to be so redeemed, or (ii)&nbsp;in the case of Definitive Notes, to each holder of
record of the Notes to be redeemed at its registered address, at a redemption price equal to 100% of their principal amount plus accrued and unpaid interest to the redemption date. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Open Market Purchases  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie or any of its affiliates may at any time and from time to time purchase Notes in the open market or otherwise. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sinking Fund  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no provision for a sinking fund for any of the Notes. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ranking  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes will be the Issuer's unsecured, unsubordinated obligations, and will:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rank equally in right of payment with all of the Issuer's existing and future unsecured, unsubordinated indebtedness, liabilities and other
obligations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rank senior in right of payment to all of the Issuer's future indebtedness that is subordinated to the Notes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be effectively subordinated in right of payment to all of the Issuer's existing and future secured indebtedness, to the extent of the value of
the assets securing such indebtedness; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be structurally subordinated in right of payment to all existing and future indebtedness, liabilities and other obligations of the Issuer's
subsidiaries. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
derives substantially all of its operating income from, and holds substantially all of its assets through, its subsidiaries. AbbVie depends on distributions of cash flow and
earnings from its subsidiaries in order to meet its payment obligations under the Notes and its other debt obligations. These subsidiaries are separate and distinct legal entities and will have no
obligation to pay any amounts due on the Notes, or to provide AbbVie with funds for its payment obligations with respect thereto, whether by dividends, distributions, loans or otherwise. As a result,
the Notes will be structurally subordinated to the liabilities of AbbVie's subsidiaries, including trade payables. In addition, provisions of applicable law, such as those limiting the payment of
dividends, could limit the ability of AbbVie's subsidiaries to make payments or other distributions to it, and AbbVie's subsidiaries </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=33,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=877066,FOLIO='S-31',FILE='DISK110:[19ZCG1.19ZCG48901]DE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_de48901_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>could
agree to contractual restrictions on their ability to pay dividends or make payments or other distributions to it. As of June&nbsp;30, 2019, on an as adjusted basis, giving effect to the
issuance and sale of the Notes and the application of the estimated net proceeds therefrom, as described in this prospectus supplement, as if such transactions had occurred on June&nbsp;30, 2019,
AbbVie would have had approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;billion of outstanding indebtedness. In addition, AbbVie has unused borrowing capacity of up to (i)&nbsp;$4&nbsp;billion under the
Revolving Credit Facility, (ii)&nbsp;$32&nbsp;billion under the Acquisition Bridge Facility and (iii)&nbsp;$6&nbsp;billion under the Acquisition Term Loan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issuance in Euro  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial holders will be required to pay for the Notes in euro, and all payments of principal of, and premium, if any, and interest on, the
Notes, including payments made upon any redemption of the Notes, will be payable in euro. If, on or after the date of this prospectus supplement, we are unable to obtain euro in amounts sufficient to
make a required payment under the Notes due to the imposition of exchange controls or other circumstances beyond our control (including the dissolution of the European Monetary Union) or if the euro
is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within
the international banking community, then all payments in respect of the Notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount
payable on any date in euro will be converted into U.S. dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second business day prior to the relevant
payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the then most recent U.S. dollar/euro exchange rate available on or prior to the
second business day prior to the relevant payment date as determined by us in our sole discretion. Any payment in respect of the Notes so made in U.S. dollar will not constitute an Event of Default
under the Notes or the indenture governing the Notes. Neither the trustee nor the paying agent shall have any responsibility for any calculation or conversion in connection with the foregoing.
Investors will be subject to foreign exchange risks as to payments of
principal and interest that may have important economic and tax consequences to them. See "Risk Factors." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Covenants of AbbVie  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restrictions on Secured Debt  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If AbbVie or any Domestic Subsidiary incurs, issues, assumes or guarantees any indebtedness for borrowed money represented by notes, bonds,
debentures or other similar evidences of indebtedness for borrowed money (called "Debt") and that Debt is secured by a Mortgage on any Principal Domestic Property or any shares of stock or Debt of any
Domestic Subsidiary, AbbVie will secure, or cause its Domestic Subsidiary to secure, the Notes equally and ratably with, or prior to, such secured Debt, so long as such secured Debt shall be so
secured, unless, after giving effect thereto, the aggregate amount of all such secured Debt, plus all Attributable Debt in respect of Sale and Leaseback Transactions involving Principal Domestic
Properties (other than Sale and Leaseback Transactions permitted pursuant to the second bullet under the heading "Restrictions on Sale and Leasebacks" below), would not exceed 15% of AbbVie's
Consolidated Net Assets. This restriction will not apply to, and there shall be excluded from secured Debt in any computation under this restriction, Debt secured
by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages on property of, or on any shares of stock or Debt of, any Person existing at the time such Person becomes a Domestic Subsidiary; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages in favor of AbbVie or any Subsidiary thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages on property of AbbVie or a Domestic Subsidiary in favor of the United States of America or any State thereof, or any department,
agency or instrumentality or political </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=34,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=739808,FOLIO='S-32',FILE='DISK110:[19ZCG1.19ZCG48901]DE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_de48901_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>subdivision
of the United States of America or any State thereof, or in favor of any other country, or any political subdivision thereof, to secure partial, progress, advance or other payments
pursuant to any contract or statute; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages on property, shares of stock or Debt existing at the time of acquisition thereof (including acquisition through merger or
consolidation); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages to secure the payment of all or any part of the cost of acquisition, construction, development or improvement of the underlying
property, or to secure debt incurred to provide funds for any such purpose, provided that the commitment of the creditor to extend the credit secured by any such Mortgage shall have been obtained not
later than 365&nbsp;days after the later of (a)&nbsp;the completion of the acquisition, construction, development or improvement of such property or (b)&nbsp;the placing in operation of such
property; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> with respect to each series of Notes, Mortgages existing on the first date on which a Note of such series is authenticated by the Trustee under
the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages incurred in connection with pollution control, industrial revenue or similar financings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mortgages created in substitution of or as replacements for any Mortgages referred to in the foregoing list, inclusive, provided that, based on
a good faith determination of an officer of AbbVie, the property encumbered under any such substitute or replacement Mortgage is substantially similar in nature to the property encumbered by the
otherwise permitted Mortgage which is being replaced; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any extension, renewal or replacement (or successive extensions, renewals or replacements), as a whole or in part, of any Debt secured by any
Mortgage referred to in the foregoing list, inclusive, provided that (i)&nbsp;such extension, renewal or replacement Mortgage shall be limited to all or a part of the same property, shares of stock
or debt that secured the Mortgage extended, renewed or replaced (plus improvements on such property, and plus any property relating to a specific project, the completion of which is funded pursuant to
clause&nbsp;(ii)(b) below), and (ii)&nbsp;the Debt secured by such Mortgage at such time is not increased (other than (a)&nbsp;by an amount equal to any related financing costs (including, but
not limited to, the accrued interest and premium, if any, on the Debt being refinanced) and (b)&nbsp;where an additional principal amount of Debt is incurred to provide funds for the completion of a
specific project that is subject to a Mortgage securing the Debt being extended, refinanced or renewed, by an amount equal to such additional principal amount). </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restrictions on Sales and Leasebacks  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither AbbVie nor any Domestic Subsidiary may enter into any Sale and Leaseback Transaction unless
either:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AbbVie or such Domestic Subsidiary could incur Debt secured by a Mortgage under the restrictions described above under "Restrictions on Secured
Debt" on the Principal Domestic Property to be leased back in an amount equal to the Attributable Debt with respect to such Sale and Leaseback Transaction without equally and ratably securing the
Notes; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AbbVie, within 180&nbsp;days after the sale or transfer by AbbVie or by any such Domestic Subsidiary, applies to the retirement of AbbVie's
Funded Debt, an amount equal to the greater of (1)&nbsp;the net proceeds of the sale of the Principal Domestic Property sold and leased back pursuant to such arrangement; or (2)&nbsp;the fair
market value of the Principal Domestic Property so sold and leased back at the time of entering into such arrangements (as determined by any two of the following: the chairman of the board of AbbVie,
its chief executive officer, an executive vice president, a senior vice president or a vice president, and the chief financial </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=35,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=652062,FOLIO='S-33',FILE='DISK110:[19ZCG1.19ZCG48901]DE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_de48901_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>officer,
the treasurer or an assistant treasurer), subject to credits for certain voluntary retirements of Funded Debt. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Definitions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following are the meanings of terms that are important in understanding the restrictive covenants of
AbbVie:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Attributable Debt" means (except as otherwise provided in this paragraph), as to any particular lease under which any Person is at the time
liable for a term of more than 12&nbsp;months, at any date as of which the amount thereof is to be determined (the "Determination Date"), the total net amount of rent required to be paid by such
Person under such lease during the remaining term thereof (excluding any subsequent renewal or other extension options held by the lessee), discounted from the respective due dates thereof to the
Determination Date at the rate of 8% per annum, compounded monthly. The net amount of rent required to be paid under any such lease for any such period shall be the aggregate amount of the rent
payable by the lessee with respect to such period after excluding amounts required to be paid on account of maintenance and repairs, services, insurance, taxes, assessments, water rates and similar
charges and contingent rents (such as those based on sales or monetary inflation). If any lease is terminable by the lessee upon the payment of a penalty, if under the terms of the lease the
termination right is not exercisable until after the Determination Date, and if the amount of such penalty discounted to the Determination Date at the rate of 8% per annum compounded monthly is less
than the net amount of rentals payable after the time as of which such termination could occur (the "Termination Time") discounted to the Determination Date at the rate of 8% per annum compounded
monthly, then such discounted penalty amount shall be used instead of such discounted amount of net rentals payable after the Termination Time in calculating the Attributable Debt for such lease. If
any lease is terminable by the lessee upon the payment of a penalty, if such termination right is exercisable on the Determination Date, and if the amount of the net rentals payable under such lease
after the Determination Date discounted to the Determination Date at the rate of 8% per annum compounded monthly is greater than the amount of such penalty, the "Attributable Debt" for such lease as
of such Determination Date shall be equal to the amount of such penalty. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Consolidated Net Assets" means the aggregate amount of assets (less applicable reserves and other properly deductible items) after deducting
therefrom all current liabilities, as set forth on the consolidated balance sheet of AbbVie and its consolidated Subsidiaries prepared as of the end of a fiscal quarter in accordance with generally
accepted accounting principles, which AbbVie shall have most recently filed with the SEC or otherwise distributed to its shareholders prior to the time as of which "Consolidated Net Assets" shall be
determined (which calculation shall give pro forma effect to any acquisition by or disposition of assets of AbbVie or any of its Subsidiaries involving the payment or receipt by AbbVie or any of its
Subsidiaries, as applicable, of consideration (whether in the form of cash or non-cash consideration) in excess of $500,000,000 that has occurred since the end of such fiscal quarter, as if such
acquisition or disposition had occurred on the last day of such fiscal quarter). </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Domestic Subsidiary" means any Subsidiary of AbbVie that transacts substantially all of its business or maintains substantially all of its
property within the United States of America (excluding its territories and possessions and Puerto Rico); provided, however, that the term shall not include any Subsidiary which (1)&nbsp;is engaged
primarily in the financing of operations outside of the United States of America or in leasing personal property or financing inventory, receivables or other property or (2)&nbsp;does not own a
Principal Domestic Property. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=36,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=507326,FOLIO='S-34',FILE='DISK110:[19ZCG1.19ZCG48901]DE48901A.;6',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg48901_1_35"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Funded Debt" means indebtedness of AbbVie (other than the Notes or indebtedness subordinated in right of payment to the Notes) or indebtedness
of a wholly-owned Domestic Subsidiary for borrowed money, having a stated maturity more than 12&nbsp;months from the date of application of Sale and Leaseback Transaction proceeds or which is
extendible at the option of the obligor thereon to a date more than 12&nbsp;months from the date of such application. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Mortgage" means any mortgage, pledge, lien, security interest, conditional sale or other title retention agreement or other similar
encumbrance. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Person" means any individual, partnership, corporation (including a business trust), joint stock company, trust, unincorporated association,
joint venture, limited liability company or other entity, or a government or any political subdivision or agency thereof. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Principal Domestic Property" means any building, structure or other facility, together with the land upon which it is erected and fixtures
comprising a part thereof, used primarily for manufacturing, processing, research, warehousing or distribution and located in the United States of America (excluding its territories and possessions
and Puerto Rico), owned or leased by AbbVie or any Domestic Subsidiary and having a net book value which, on the date the determination as to whether a property is a Principal Domestic Property is
being made, exceeds 2% of Consolidated Net Assets of AbbVie other than any such building, structure or other facility or a portion thereof (i)&nbsp;which is an air or water pollution control
facility financed by State or local governmental obligations or (ii)&nbsp;which the chairman of the board, chief executive officer, an executive vice president, a senior vice president or a vice
president and the chief financial officer, treasurer or assistant treasurer of AbbVie determine in good faith, at any time on or prior to such date, is not of material importance to the total business
conducted, or assets owned, by AbbVie and its Subsidiaries as an entirety. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Sale and Leaseback Transaction" means any arrangement with any bank, insurance company or other lender or investor (not including AbbVie or
any Subsidiary) or to which any such lender or investor is a party, providing for the leasing by AbbVie or any Domestic Subsidiary for a period, including renewals, in excess of three years of any
Principal Domestic Property which has been or is to be sold or transferred, more than 180&nbsp;days after the acquisition thereof or the completion of construction and commencement of full operation
thereof, by AbbVie or any Domestic Subsidiary to such lender or investor or to any person to whom funds have been or are to be advanced by such lender or investor on the security of such Principal
Domestic Property. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Subsidiary" means any Person which is a corporation, partnership, joint venture, limited liability company, trust or estate, and of which
AbbVie directly or indirectly owns or controls stock or other interests, which under ordinary circumstances (not dependent upon the happening of a contingency) has the voting power to elect a majority
of the board of directors, managers, trustees or equivalent of such Person; provided, however, that the term shall not include any such Person if and for so long as (i)&nbsp;such Person does not own
a Principal Domestic Property and (ii)&nbsp;the chairman of the board, chief executive officer, an executive vice president, a senior vice president or a vice president and the chief financial
officer, treasurer or assistant treasurer of AbbVie determine in good faith at least annually that the existing aggregate investments by AbbVie and its Domestic Subsidiaries (including all guarantees
and other extensions of credit) in such Person are not of material importance to the total business conducted, or assets owned, by AbbVie and its Subsidiaries, as an entirety. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Trustee" means the Person named as the "Trustee" in the indenture until a successor Trustee shall have become such pursuant to the applicable
provisions of the indenture, and thereafter "Trustee" shall mean or include each Person who is then a Trustee under the indenture, and if </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=37,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=905864,FOLIO='S-35',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dg48901_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>at
any time there is more than one such Person, "Trustee" as used with respect to the Notes of any series shall mean the Trustee with respect to the Notes of that series. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consolidation, Merger and Sale of Assets  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie shall not consolidate with or merge into any other Person or convey, transfer or lease its properties and assets substantially as an
entirety to any Person, unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Person formed by such consolidation or into which AbbVie is merged or the Person which acquires by conveyance or transfer, or which leases,
AbbVie's properties and assets substantially as an entirety shall be a corporation, limited liability company or partnership, shall be organized and validly existing under the laws of the United
States of America, any State thereof or the District of Columbia and shall expressly assume AbbVie's obligations on the Notes under a supplemental indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> immediately after giving effect to such transaction and treating any indebtedness which becomes an obligation of AbbVie or a Subsidiary as a
result of such transaction as having been incurred by AbbVie or such Subsidiary at the time of such transaction, no event of default, and no event which, after notice or lapse of time or both, would
become an event of default, shall have happened and be continuing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if, as a result of any such consolidation or merger or such conveyance, transfer or lease, AbbVie's properties or assets would become subject
to a mortgage, pledge, lien, security interest or other encumbrance which would not be permitted by the indenture, AbbVie or such successor Person, as the case may be, shall take such steps as shall
be necessary to effectively secure the Notes equally and ratably with, or prior to, all indebtedness secured thereby; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AbbVie has delivered to the Trustee an officers' certificate and an opinion of counsel stating compliance with these provisions. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
any consolidation of AbbVie with, or merger of AbbVie into, any other Person or any conveyance, transfer or lease of the properties and assets of AbbVie substantially as an entirety
in accordance with the above provisions, the successor Person formed by such consolidation or into which AbbVie is merged or to which such conveyance, transfer or lease is made shall succeed to, and
be substituted for, and may exercise every right and power of, AbbVie under the indenture with the same effect as if such successor Person had been named in the indenture, and thereafter, except in
the case of a lease, the predecessor Person shall be relieved of all obligations and covenants under the indenture and the Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
phrase "substantially as an entirety," as used with respect to our assets and properties in this covenant, is subject to interpretation under applicable state law, and its
applicability in a given instance would depend upon the facts and circumstances. Although there is a limited body of case law interpreting the phrase "substantially as an entirety," there is no
precise established definition of the phrase under applicable law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
the applicability of the requirement that any Person assume AbbVie's obligations on the Notes in connection with any conveyance, transfer or lease of AbbVie's properties and
assets may be uncertain. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Events of Default  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture defines an event of default with respect to any series of Notes as being: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>failure
to pay interest or premium on that series of Notes when due, continued for a period of 30&nbsp;days; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=38,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=995310,FOLIO='S-36',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dg48901_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>failure
to pay the principal on that series of Notes when due;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>failure
to perform, or breach, under any other covenant or warranty applicable to that series of Notes and not otherwise specifically dealt with in the definition of
"event of default," continued for a period of 90&nbsp;days after the giving of written notice to AbbVie by the Trustee or to AbbVie and the Trustee by holders of at least 25% in principal amount of
outstanding Notes of that series (provided that such notice may not be given with respect to any action taken, and reported publicly or to holders of the Notes, more than two years prior to such
notice); or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>specified
events of bankruptcy, insolvency or reorganization of AbbVie. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Trustee is required to give holders of the particular series of Notes written notice of a default with respect to that series as provided by the Trust Indenture Act. In the case of
any default of the character described above in clause&nbsp;(3) of the immediately preceding paragraph, no such notice to holders must be given until at least 60&nbsp;days after the occurrence of
that default. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
is required annually to deliver to the Trustee a certificate stating whether or not the signers have any knowledge of any default by AbbVie in its performance and observance of
any terms, provisions and conditions of the indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
case an event of default (other than an event of default involving an event of bankruptcy, insolvency or reorganization of AbbVie) shall occur and be continuing with respect to any
series of Notes, the Trustee or the holders of not less than 25% in principal amount of the particular series of Notes then outstanding may declare the principal amount of such series of Notes to be
immediately due and payable. If an event of default relating to any event of bankruptcy, insolvency or reorganization of AbbVie occurs, the principal of all the Notes then outstanding will become
immediately due and payable without any action on the part of the Trustee or any holder. The holders of a majority in principal amount of the outstanding series of Notes affected by the default may in
some cases rescind this accelerated payment requirement. Depending on the terms of AbbVie's other indebtedness, an event of default in respect of the Notes may give rise to cross defaults on its other
indebtedness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
past default with respect to a series of Notes may be waived on behalf of all holders of that series of Notes by at least a majority in principal amount of the holders of the
outstanding Notes of that series, except a default:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the payment of the principal of or any premium or interest on that series of Notes; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in respect of a covenant or provision which under the indenture cannot be modified or amended without the consent of the holder of each
outstanding Note of that series affected. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
default that is so waived will cease to exist and any event of default arising from that default will be deemed to be cured and shall cease to exist for every purpose under the
indenture, but no such waiver will extend to any subsequent or other default or impair any right consequent thereon. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
holder of Notes of any series will be able to pursue any remedy under the indenture only if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such holder has previously given written notice to the Trustee of a continuing event of default with respect to that series of Notes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holders of not less than 25% in principal amount of the outstanding Notes of that series shall have made written request to the Trustee to
institute proceedings in respect of such event of default in its own name as Trustee under the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such holders or holders making the request have offered to the Trustee reasonable indemnity against the costs, expenses and liabilities to be
incurred in compliance with such request; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=39,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=521721,FOLIO='S-37',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dg48901_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Trustee for 60&nbsp;days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> during that 60-day period, the holders of a majority in principal amount of that series of Notes do not give the Trustee a direction
inconsistent with such request. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of Notes, however, are entitled at any time to bring a lawsuit for the payment of principal and interest due on their Notes on or after its due date. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
time period in the indenture to cure any actual or alleged default or event of default may be extended or stayed by a court of competent jurisdiction. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Modification of the Indenture  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie and the Trustee may modify the indenture or any supplemental indenture without the consent of the holders of the Notes for one or more of
the following purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to evidence the succession of another Person to AbbVie and the assumption by any such successor of the obligations of AbbVie in the indenture
or any supplemental indenture, and in the Notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to the covenants of AbbVie for the benefit of the holders of all or any series of Notes or to surrender any right or power conferred
upon AbbVie by the indenture or any supplemental indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add any additional events of default for the benefit of holders of all or any series of Notes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to or change any of the provisions of the indenture or any supplemental indenture to such extent as shall be necessary to permit or
facilitate the issuance of debt securities in certain other forms; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to, change or eliminate any of the provisions of the indenture or any supplemental indenture in respect of one or more series of Notes,
provided that any such addition, change or elimination (i)&nbsp;shall neither (A)&nbsp;apply to any Note of any series created prior to the execution of such supplemental indenture affecting such
modification and entitled to the benefit of such provision nor (B)&nbsp;modify the rights of the holder of any such Note with respect to such provision or (ii)&nbsp;shall become effective only
when there is no such Note outstanding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to secure the Notes pursuant to the requirements of the indenture or the requirements of any supplemental indenture or to otherwise provide any
security for, or add any guarantees of or additional obligors on, the Notes of all or any series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to establish the form or terms of Notes of any series in accordance with the terms of the indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to supplement any of the provisions of the indenture to such extent as shall be necessary to permit or facilitate the defeasance and discharge
of a particular series of Notes in accordance with the provisions in the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to evidence and provide for the acceptance of the appointment of a successor trustee with respect to the Notes of one or more series and to add
to or change any of the provisions of the indenture or any supplemental indenture as shall be necessary to provide for or facilitate the administration of the trusts under such indenture or
supplemental indenture by more than one trustee pursuant to the requirements set forth in the indenture; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to cure any ambiguity or to correct or supplement any provision of the indenture or any supplemental indenture which may be defective or
inconsistent with any other provision in the indenture or any supplemental indenture, or to make any other provisions with respect to </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=40,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=129572,FOLIO='S-38',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dg48901_1_39"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>matters
or questions arising under the indenture or any supplemental indenture as shall not adversely affect the interests of the holders of any series of Notes in any material respect. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
and the Trustee may otherwise modify the indenture or any supplemental indenture with the consent of the holders of not less than a majority in principal amount of each series of
Notes affected for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the indenture or of modifying in any manner the rights of the holders of
Notes of such series under the indenture or any supplemental indentures. However, without the consent of the holder of each outstanding Note affected by such modification, no modification
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> change the stated maturity of the principal of, or any installment of principal of or interest thereon, or reduce the principal amount thereof
or the rate of interest thereon or any premium payable upon the redemption thereof, or change any place of payment where, or the coin or currency in which, such Notes or any premium or interest
thereon is payable, or impair the right to institute suit for the enforcement of any such payment on or after the stated maturity thereof (or, in the case of redemption, on or after the redemption
date); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduce the percentage in principal amount of the Notes of any series, the consent of whose holders is required in the indenture for consent for
any waiver of compliance with certain provisions of the indenture or certain defaults under the indenture and their consequences; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> modify the provisions set forth in the two bullets above or the paragraph immediately preceding the two bullets above or modify provisions
relating to the waiver of past defaults or the waiver of certain covenants in the indenture, in each case, other than to increase the percentage in principal amount of the Notes required to modify
such provisions or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of the holder of each outstanding Note affected by such modification. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Defeasance and Covenant Defeasance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of the indenture relating to defeasance and covenant defeasance as described in the indenture will apply to the Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
indenture provides that, at AbbVie's option, AbbVie:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> will be discharged from any and all obligations in respect of the Notes of a series, except for certain obligations set forth in the indenture
that survive such discharge ("legal defeasance"); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> may omit to comply with certain restrictive covenants of the indenture, including those described under "Certain Covenants of AbbVie" and
"Consolidation, Merger and Sale of Assets," and the occurrence of an event described in clause&nbsp;(3) under "Events of Default" with respect to any such covenants will no longer be an event of
default ("covenant defeasance"); </FONT></DD></DL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>in
each case, if </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AbbVie irrevocably deposits or causes to be deposited with the Trustee, as trust funds in trust for the purpose of making the following
payments, specifically pledged as security for, and dedicated solely to, the benefit of the holders of such Notes, in money in an amount, euro-denominated government instruments, which through the
scheduled payment of principal and interest in respect thereof in accordance with their terms will provide, not later than one day before the due date of any payment, money in an amount, or a
combination thereof, sufficient, without reinvestment, in the opinion of a nationally recognized firm of independent public accountants to pay and discharge all the principal of and premium, if any,
and interest on the Notes of that series on the dates such payments are due, which may include one or more redemption dates that AbbVie designates, in accordance with the terms of the Notes of that
series; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=41,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=898919,FOLIO='S-39',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dg48901_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no event of default or event which with notice or lapse of time, or both, would become an event of default with respect to Notes of such series
shall have occurred and be continuing on the date of such deposit or insofar as an event of default resulting from certain events involving AbbVie's bankruptcy or insolvency are concerned, at any time
during the period ending on the 121st&nbsp;day after such date of the deposit or, if longer, ending on the day following the expiration of the longest preference period applicable to AbbVie in
respect of such deposit (it being understood that this condition will not be deemed satisfied until the expiration of such period); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such defeasance will not cause the Trustee to have a conflicting interest with respect to any of AbbVie's securities or result in the trust
arising from such deposit to constitute, unless it is qualified as, a regulated investment company under the Investment Company Act of 1940, as amended; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the defeasance will not result in a breach or violation of, or constitute a default under, the indenture or any other agreement or instrument
to which AbbVie is a party or by which AbbVie is bound; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AbbVie has delivered an opinion of counsel to the effect that the beneficial owners of Notes will not recognize income, gain or loss for
federal income tax purposes as a result of the defeasance and will be subject to federal income tax in the same manner as if the defeasance had not occurred, which opinion of counsel, in the case of
legal defeasance, must refer to and be based upon a published ruling of the Internal Revenue Service, a private ruling of the Internal Revenue Service addressed to AbbVie, or otherwise a change in
applicable federal income tax law occurring after the date of the indenture; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> AbbVie shall have delivered an officer's certificate and an opinion of counsel stating that the conditions to such defeasance set forth in the
indenture have been complied with. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
AbbVie fails to comply with its remaining obligations under the indenture after a covenant defeasance with respect to the Notes of any series and the Notes of such series are declared
due and payable because of the occurrence of any event of default, the amount of money and euro-denominated government instruments on deposit with the Trustee may be insufficient to pay amounts due on
the Notes of that series at the time of the acceleration resulting from the event of default. AbbVie will, however, remain liable for those payments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Satisfaction and Discharge  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture will be discharged and will cease to be of further effect (except as to any surviving rights of registration of transfer or
exchange of Notes, as expressly provided for in the indenture) as to all outstanding Notes of any series when: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;either
(a)&nbsp;all the Notes of such series theretofore authenticated and delivered (except lost, stolen or destroyed Notes which have been replaced or paid and Notes
for whose payment money has theretofore been deposited in trust or segregated and held in trust by AbbVie and thereafter repaid to it or discharged from such trust) have been delivered to the Trustee
for cancellation or (b)&nbsp;all of the Notes of such series not theretofore delivered to the Trustee for cancellation (i)&nbsp;have become due and payable, (ii)&nbsp;will become due and payable
at their stated maturity within one year or (iii)&nbsp;if redeemable at AbbVie's option, are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving
of notice of redemption by the Trustee in the name, and at the expense, of AbbVie, and AbbVie has irrevocably deposited or caused to be deposited with the Trustee funds in an amount sufficient to pay
and discharge the entire indebtedness on the Notes of such series not theretofore delivered to the Trustee for cancellation, for principal of, premium, if any, and interest on the Notes of such series
to the date of such deposit (in the case of Notes which have become due and payable), or to </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=42,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=234803,FOLIO='S-40',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dg48901_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>their
stated maturity or the redemption date, as the case may be (provided that in connection with any discharge relating to any redemption that requires the payment of a premium, the amount deposited
shall be sufficient for purposes of the indenture to the extent that an amount is deposited with the Trustee equal to the premium calculated as of the date of the notice of redemption, with any
deficit as of the redemption date only required to be deposited with the Trustee on or prior to the redemption date), together with irrevocable instructions from AbbVie directing the Trustee to apply
such funds to the payment thereof at maturity or redemption, as the case may be; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;AbbVie
has paid or caused to be paid all other sums payable under the indenture in respect of such series of Notes; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;AbbVie
has delivered to the Trustee an officers' certificate and an opinion of counsel, each stating that all conditions precedent under the indenture relating to the
satisfaction and discharge of the indenture with respect to such series of Notes have been complied with. </FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governing Law  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture and the Notes shall be governed by and construed in accordance with the laws of the State of New York. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Trustee  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Bank National Association will be named as the "Trustee" under the indenture. U.S. Bank National Association and its affiliates perform
certain commercial banking services for some of AbbVie's affiliates for which they receive customary fees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Trustee will become obligated to exercise any of its powers under the indenture at the request or direction of any of the holders of any Notes pursuant to the indenture only after
those holders have offered the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by the Trustee in compliance with such request or direction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
U.S. Bank National Association, nor any of its affiliates, in each of their capacities including, but not limited to, Trustee, paying agent and security registrar, have
participated in the preparation of this prospectus supplement and assumes no responsibility for its content. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
considering the interests of holders of the Notes while any relevant Global Notes are held on behalf of Euroclear and Clearstream, Luxembourg, the Trustee may have regard to any
information provided to it by such clearing systems as to the identity (either individually or by category) of their accountholders and may consider such interests as if such accountholders were
holders of the relevant Global Notes and interests therein. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment and Paying Agents  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie will make payments on the Notes in euro at the office of the Trustee, the London Paying Agent or any paying agent AbbVie designates
(which paying agent may include AbbVie). At its option, AbbVie may make payments of interest by (1)&nbsp;check mailed to the address of the Person entitled thereto as such address shall appear in
the security register or (2)&nbsp;wire transfer as directed by the holder of any Note, in immediately available funds to an account maintained by the applicable depository or its nominee with
respect to a Global Note, and to the holder of any Note or its nominee with respect to a Definitive Note; provided further that in the case of a Definitive Note&nbsp;(x) the holder thereof shall
have provided written wiring instructions to the London Paying Agent on or before the related Record Date and (y)&nbsp;if appropriate instructions for any such wire transfer are not received by the
related Record Date, then such payment shall be made by check mailed to the address of such holder specified in the security register. AbbVie will make interest payments to the holder in whose name
the Note is registered at the close of business on the Record Date for the interest payment. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=43,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=232741,FOLIO='S-41',FILE='DISK110:[19ZCG1.19ZCG48901]DG48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di48901_1_42"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All payments of any amounts paid to or to the order of the nominee for a common depositary for Euroclear and Clearstream, Luxembourg shall be valid and, to the
extent of the sums so paid, effectual to satisfy and discharge the liability of AbbVie for the moneys payable on the Notes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
has designated the London Paying Agent as its paying agent for payments on Notes. AbbVie may at any time designate additional paying agents or rescind the designation of any
paying agent or approve a change in the office through which any paying agent acts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Trustee or London Paying Agent, as applicable, will repay to AbbVie on AbbVie's written request any funds they hold for payments on the Notes that remain unclaimed for two years
after the date upon which that payment has become due. After repayment to AbbVie, holders entitled to those funds must look only to it for payment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exchange, Registration and Transfer  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes of any series may be exchangeable for other Notes of the same series with the same total principal amount and the same terms but in
different authorized denominations in accordance with the indenture. Holders may present registered Notes for registration of transfer at the office of the security registrar. The security registrar
will effect the transfer or exchange when it is satisfied with the documents of title and identity of the person making the request. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
will appoint the Trustee as security registrar for the Notes. AbbVie may at any time designate additional security registrars for any series of Notes or rescind the designation of
any security registrar or approve a change in the location through which any security registrar acts. AbbVie will be required to maintain an office or agency for transfers and exchanges in each place
of payment. No service charge will be made for any registration of transfer or exchange of the Notes, but we or the security registrar may require payment of a sum sufficient to cover any transfer
tax, assessments, or similar governmental charge payable in connection therewith (other than as set forth in the indenture). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
AbbVie nor the security registrar will be required to register the transfer of or exchange of any Note:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> during a period beginning at the opening of business 15&nbsp;days before the day of the mailing of a notice of redemption of Notes of that
series selected for redemption and ending at the close of business on the day of such mailing; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> so selected for redemption in whole or in part, except the unredeemed portion of any Note being redeemed in part. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notices  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;So long as any Notes are represented by a Global Note and such Global Note is held on behalf of a clearing system, notices to the holders of
Notes of that series may be given by
delivery of the relevant notice to that clearing system for communication by it to entitled accountholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Book-Entry System  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will issue the Notes initially in the form of Global Notes in fully registered, book-entry form. The Global Notes will be registered in the
name of a nominee for, and delivered to, a common depositary for Euroclear and Clearstream, Luxembourg. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described below, the Global Notes may be transferred, in whole but not in part, only to another nominee of Euroclear and Clearstream, Luxembourg. Beneficial interests in the
Global Notes may not be exchanged for Definitive Notes except in the limited circumstances described below. See "&#151;Exchange of Global Notes for Definitive Notes" below. Except in the
limited circumstances </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=44,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=689154,FOLIO='S-42',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_di48901_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>described
below, owners of beneficial interests in the Global Notes will not be entitled to receive Definitive Notes. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Euroclear and Clearstream, Luxembourg  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial interests in the Global Notes will be represented through book-entry accounts of financial institutions acting on behalf of
beneficial owners as accountholders in Euroclear and Clearstream, Luxembourg. Investors may hold interests in the Global Notes through either Euroclear or Clearstream, Luxembourg, either directly if
they are accountholders in such systems, or indirectly through organizations that are accountholders in such systems. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have obtained the information in this section concerning Euroclear and Clearstream, Luxembourg and the book-entry system and procedures from sources that we believe to be reliable,
but we take no responsibility for the accuracy of this information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Euroclear
and Clearstream, Luxembourg each holds securities for its customers and facilitates the clearance and settlement of securities transactions by electronic book-entry transfer
between their respective accountholders. Euroclear and Clearstream, Luxembourg provide various services including safekeeping, administration, clearance and settlement of internationally traded
securities and securities lending and borrowing. Euroclear and Clearstream, Luxembourg also deal with domestic securities markets in several countries through established depository and custodial
relationships. Euroclear and Clearstream, Luxembourg have established an electronic bridge between their two systems across which their respective participants may settle trades with each other. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Euroclear
and Clearstream, Luxembourg customers are world-wide financial institutions, including underwriters, securities brokers and dealers, banks, trust companies and clearing
corporations. Indirect access to Euroclear and Clearstream, Luxembourg is available to other institutions that clear through or maintain a custodial relationship with an accountholder of either
system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfers
of any interests in Notes represented by a Global Note within Euroclear and Clearstream, Luxembourg will be effected in accordance with the customary rules and operating
procedures of the relevant clearing system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or after the issue date of the Notes, transfers of Notes represented by a Global Note between accountholders in Euroclear and Clearstream, Luxembourg will generally have a settlement
date three business days after the trade date (T+3). The customary arrangements for delivery versus payment will apply to such transfers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clearstream,
Luxembourg and Euroclear have each published rules and operating procedures designed to facilitate transfers of beneficial interests in Global Notes among participants and
accountholders of Clearstream, Luxembourg and Euroclear. However, they are under no obligation to perform or continue to perform such procedures, and such procedures may be discontinued or changed at
any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Issuer, the Trustee, the London Paying Agent or any underwriter will be responsible for any performance by Clearstream, Luxembourg or Euroclear or their accountholders of
their respective obligations under the rules and procedures governing their operations and none of them will have any liability for any aspect of the records relating to or payments made on account of
beneficial interests in the Notes represented by a Global Note or for maintaining, supervising or reviewing any records relating to such beneficial interests. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Same-Day Settlement and Payment  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie will make payments in respect of the Notes represented by the Global Notes (including principal, premium, if any, and interest) by wire
transfer of immediately available funds to the account </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=45,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=139372,FOLIO='S-43',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_di48901_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>specified
by the London Paying Agent; provided, however, that at AbbVie's option payment of interest in respect of Definitive Notes may be made by (1)&nbsp;check mailed to the address of the person
entitled thereto as such address shall appear in the security register or (2)&nbsp;wire transfer as directed by the holder of the relevant Notes, in immediately available funds to accounts
maintained by the holder of Notes or its nominee; provided further that in the case of a Definitive Note&nbsp;(x) the holder thereof shall have provided written wiring instructions to the London
Paying Agent on or before the related Record Date and (y)&nbsp;if appropriate instructions for any such wire transfer are not received by the related Record Date, then such payment shall be made by
check mailed to the address of such holder specified in the security register. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the principal of or any premium or interest on the Notes is payable on a day that is not a Payment Business Day, the payment will be made on the following Payment Business Day without
the accrual of any interest on that payment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
these purposes "Payment Business Day" means any day that is: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
day on which commercial banks and foreign exchange markets settle payments and are open for general business (including dealing in foreign exchange and foreign
currency deposits) in, in the case of Definitive Notes only, the relevant place of presentation;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
day on which the TARGET 2 System is open, and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
the case of any payment in respect of a Global Note, a day on which Euroclear and/or Clearstream, Luxembourg, as the case may be, settle(s) payments in euro. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
these purposes "TARGET 2 System" means the Trans-European Automatic Real-Time Gross Settlement Express Transfer (TARGET 2)&nbsp;System. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exchange of Global Notes for Definitive Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie will issue Definitive Notes upon surrender of the Global Notes in accordance with their terms only if: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>an
event of default has occurred and is continuing; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>either
Euroclear or Clearstream, Luxembourg is closed for business for a continuous period of 14&nbsp;days or more (other than by reason of holiday, statutory or
otherwise) or announces an intention permanently to cease business or does in fact do so and no alternative clearing system satisfactory to the Trustee is available; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
Issuer would suffer a disadvantage as a result of a change in laws or regulations (taxation or otherwise) or as a result of a change in the practice of Euroclear
and/or Clearstream, Luxembourg which would not be suffered were the Notes in definitive form and a certificate to such effect signed by an authorised signatory of the Issuer is given to the Trustee. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thereupon
(in the case of (a)&nbsp;or (b)&nbsp;above) the holder of a Global Note (acting on behalf of one or more of the accountholders) or the Trustee may give notice to the Issuer
and (in the case of (c)&nbsp;above) the Issuer may give notice to the Trustee and the holders of Notes, of its intention to exchange a Global Note for Definitive Notes on or after the Exchange Date
(as defined below). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or after the Exchange Date the holder of the Global Note may, or in the case of (c)&nbsp;above, shall surrender it to or to the order of the London Paying Agent. In exchange for the
Global Note, the
Issuer shall deliver, or procure the delivery of, an equal aggregate principal amount of Definitive Notes, security printed in accordance with any applicable legal and stock exchange requirements. On
exchange of the Global Note, the Issuer will procure that it is cancelled and, if the holder so requests, returned to the holder together with any relevant Definitive Notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=46,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=653842,FOLIO='S-44',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_di48901_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
these purposes, "Exchange Date" means a day specified in the notice requiring exchange falling not less than 60&nbsp;days after that on which the notice requiring exchange is given
and being a day on which banks are open for general business in London, the place in which the specified office of the London Paying Agent is located and, except in case of exchange pursuant to
(b)&nbsp;above, in the place in which Euroclear and Clearstream, Luxembourg are located. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases, Definitive Notes delivered in exchange for any Global Note or beneficial interests in Global Notes will be registered in the names, and issued in any approved
denominations, requested by or on behalf of the holder of the relevant Global Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor the Trustee will be liable for any delay by the holder of the relevant Global Notes in identifying the holders of beneficial interests in the Global Notes, and each such
person may conclusively rely on, and will be protected in relying on, instructions from Euroclear or Clearstream, Luxembourg for all purposes (including with respect to the registration and delivery,
and the respective principal amounts, of the Definitive Notes to be issued). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=47,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=683798,FOLIO='S-45',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_di48901_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di48901_material_u.s._federal_income_tax_considerations"> </A>
<A NAME="toc_di48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a general discussion of the material U.S. federal income tax considerations that may be relevant to U.S. Holders and Non-U.S.
Holders (each as defined below and collectively referred to as "Holders") with respect to the ownership and disposition of the Notes
acquired in this offering, but does not purport to be a complete analysis of all the potential tax considerations. This discussion is based on the Internal Revenue Code of 1986, as amended (the
"Code"), the Treasury regulations promulgated thereunder, and administrative rulings of the Internal Revenue Service ("IRS") and judicial decisions, each as in effect as of the date hereof. These
authorities are subject to differing interpretations and may change, possibly on a retroactive basis, and any such change could affect the accuracy of the statements and conclusions set forth herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion applies only to Holders that purchase Notes in the initial offering at their original "issue price" (</FONT><FONT SIZE=2><I>i.e</I></FONT><FONT SIZE=2>., the first price
at which a substantial amount of the Notes is sold to purchasers (other than bond houses, brokers or similar persons or organizations acting in the capacity of underwriters, placement agents or
wholesalers) for cash) and hold Notes as "capital assets" within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address tax
considerations applicable to subsequent purchasers of the Notes. This discussion does not address all aspects of U.S. federal income taxation that may be relevant to particular investors in light of
their individual circumstances or the U.S. federal income tax consequences applicable to Holders that are subject to special rules under the U.S. federal income tax laws including, for example, banks
and other financial institutions, insurance companies, tax-exempt organizations, partnerships or other pass-through entities (or investors therein), individual retirement and other tax deferred
accounts, dealers or traders in securities or currencies, regulated investment companies, real estate investment trusts, U.S. Holders whose "functional currency" is not the U.S. dollar, traders in
securities that elect a mark-to-market method of tax accounting, "controlled foreign corporations," "passive foreign investment companies," U.S. expatriates, non-U.S. trusts and estates that have U.S.
beneficiaries, and persons holding Notes as part of a hedge, straddle, conversion transaction or other integrated transaction or risk reduction transaction. This discussion does not address the tax
consequences of the ownership or disposition of Notes arising under the alternative minimum tax, the unearned income Medicare contribution tax pursuant to the Health Care and Education Reconciliation
Act of 2010 or rules requiring the recognition of any item of gross income with respect to the Notes as a result of such income being recognized on an applicable financial statement, and does not
address any U.S. federal tax laws other than those pertaining to the income tax, nor does it address any foreign, state or local tax consequences. We have not sought, and will not seek, any ruling
from the IRS with respect to the statements made and the conclusions reached in this discussion, and we cannot assure you that the IRS will agree with such statements and conclusions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used herein, a "U.S. Holder" means a beneficial owner of a Note that is, for U.S. federal income tax purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an individual who is a citizen or resident of the United States for U.S. federal income tax purposes; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a corporation (or other entity classified as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of
the United States, any state within the United States, or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income tax regardless of its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a trust if (i)&nbsp;a court within the United States is able to exercise primary supervision over the administration of the trust and one or
more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&nbsp;the trust validly elected to be treated as a U.S. person under applicable Treasury regulations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=48,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=335227,FOLIO='S-46',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_di48901_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used herein, a "Non-U.S. Holder" is a beneficial owner of a Note that is, for U.S. federal income tax purposes, an individual, corporation, trust, or estate that is not a U.S. Holder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Notes, the U.S. federal income tax treatment of a partner in such entity will generally
depend upon the status of the partner and the activities of the entity. Holders of Notes that are partnerships or partners in such entities should consult their own tax advisors regarding the tax
consequences to them of the purchase, ownership and disposition of Notes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS
DISCUSSION IS FOR GENERAL INFORMATION ONLY AND IS NOT INTENDED TO CONSTITUTE A COMPLETE DESCRIPTION OF ALL TAX CONSEQUENCES RELATING TO THE OWNERSHIP AND DISPOSITION OF NOTES.
PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF OWNING AND DISPOSING OF THE NOTES, AS WELL AS THE APPLICATION AND EFFECT OF ANY STATE,
LOCAL AND FOREIGN INCOME AND OTHER TAX LAWS. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms of the Notes provide for payments by us in excess of stated interest or principal, or prior to their scheduled payment dates, under certain circumstances. The possibility of
such payments may implicate special rules under Treasury regulations governing "contingent payment debt instruments." According to those Treasury regulations, the possibility that such payments of
excess or accelerated amounts will be made will not affect the amount of income a Holder recognizes in advance of the payment of such excess or accelerated amounts if there is only a remote chance as
of the date the
Notes are issued that such payments will be made. We believe and intend to take the position that the likelihood that such payments of excess or accelerated amounts will be made is remote within the
meaning of the applicable Treasury regulations. The remainder of this discussion assumes that this position will be respected. Our position that these contingencies are remote is binding on a Holder
unless such Holder discloses its contrary position to the IRS in the manner required by applicable Treasury regulations. Our position is not, however, binding on the IRS, and if the IRS were to
challenge this position successfully, a Holder might be required, among other things, to accrue interest income based on a projected payment schedule and comparable yield, which may be in excess of
stated interest, and treat as ordinary income rather than capital gain any income realized on the taxable disposition of a Note. In the event a contingency described above occurs, it would affect the
amount, timing and character of the income or loss recognized by a Holder. Prospective investors should consult their own tax advisors regarding the tax consequences if the Notes were treated as
contingent payment debt instruments. The remainder of this discussion assumes that the Notes will not be considered contingent payment debt instruments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain U.S. Federal Income Tax Considerations for U.S. Holders  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payments of Interest  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments of stated interest on a Note will generally be taxable to U.S. Holders as ordinary interest income at the time such interest payments
are accrued or received, depending on such U.S. Holder's regular method of accounting for U.S. federal income tax purposes. It is anticipated, and this discussion assumes, that the issue price of the
Notes will be equal to the stated principal amount or, if the issue price is less than the stated principal amount, that the difference will be less than a </FONT><FONT SIZE=2><I>de
minimis</I></FONT><FONT SIZE=2> amount (as set forth in the applicable Treasury regulations). If a Holder uses the cash method of accounting for U.S. federal income tax purposes, such Holder will be
required to include in such Holder's gross income the dollar value of the euro interest payment on the date received (based on the dollar spot rate for euro on that date), regardless of whether the
Holder in fact converts the payment to dollars at that time. A Holder will not recognize foreign currency gain or loss with respect to receipt of such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=49,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=484474,FOLIO='S-47',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_di48901_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>payments,
but may have foreign currency gain or loss when such Holder actually sells or otherwise disposes of euro, as described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Holder uses the accrual method of accounting for U.S. federal income tax purposes, such Holder will be required to include in such Holder's gross income the dollar value of the euro
amount of interest income that accrues during an accrual period. The dollar value of the euro amount of accrued interest income is determined by translating that income at the average dollar exchange
rate for euro in effect during the accrual period or, if the accrual period spans two taxable years, the partial period within the taxable year. A Holder may elect, however, to translate accrued
interest income using: (i)&nbsp;the dollar spot rate for euro on the last day of the accrual period, (ii)&nbsp;in the case of a partial accrual period, the spot rate on the last day of the taxable
year or (iii)&nbsp;if the date of receipt is within five business days of the last day of the interest accrual period, the spot rate on the date of receipt. That election must be applied
consistently to all debt instruments&nbsp;a Holder holds from year to year and may not be changed without the consent of the IRS. Prior to making any such election, Holders should consult their own
tax advisors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Holder uses the accrual method of accounting for U.S. federal income tax purposes, such Holder may recognize foreign currency gain or loss, which generally will be taxable as
ordinary income or loss, with respect to accrued interest income on the date the payment of that income was received. The amount of foreign currency gain or loss recognized will be the difference, if
any, between the dollar value of the payment in euro that is received by the Holder in respect of the accrued interest (based on the dollar spot rate for euro on the date the Holder receives the
payment) and the dollar value of interest income that has accrued during the accrual period (determined as described in the preceding paragraph). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Holder receives a payment of interest in dollars as a result of a currency conversion, then the dollar amount so received might not be the same as the dollar amount required to be
recognized as interest income under the rules described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exchange or Purchase of Euro  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Euro received as interest on a Note or on a sale, exchange, redemption or other disposition of a Note generally will have a tax basis equal to
the dollar value of the euro at the spot rate on the date of receipt. If a Holder purchases euro, the tax basis of the euro will generally be the dollar value of the euro at the spot rate on the date
of purchase. Any gain or loss recognized on a sale,
exchange or other disposition of euro (including the use of euro to purchase Notes or upon the exchange of euro for dollars) generally will be treated as ordinary income or loss. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale, Exchange, Redemption or Other Taxable Disposition of the Notes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a Holder receives euro on the sale, exchange, redemption or other disposition of a Note, the dollar amount realized generally will be based
on the dollar spot rate for euro on the date of the disposition. However, if the Notes are traded on an established securities market and such Holder is a cash-method U.S. Holder or an electing
accrual-method U.S. Holder, the dollar amount realized will be determined by translating the euro received at the dollar spot rate for euro on the settlement date of the disposition. If such Holder is
an accrual-method U.S. Holder and makes this election, the election must be applied consistently to all debt instruments from year to year and cannot be changed without the consent of the IRS. If such
Holder is an accrual-method U.S. Holder and does not make this election, the dollar equivalent of the amount realized will be determined by translating that amount at the dollar spot rate for euro on
the date of the sale, exchange, redemption or other disposition and generally will recognize foreign currency gain or loss (generally treated as ordinary income or loss) equal to the difference, if
any, between the dollar equivalent of the amount realized based on the spot rates in effect on the date of disposition and the settlement date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=50,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=427896,FOLIO='S-48',FILE='DISK110:[19ZCG1.19ZCG48901]DI48901A.;5',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk48901_1_49"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial tax basis in a Note generally will be the cost of the Note, which, in the case of a U.S. Holder that purchases a Note with euro, will be the dollar
value of the amount of euro paid for such Note at the dollar spot rate for euro on the date of purchase. However, if the Notes are traded on an established securities market, and a Holder is a
cash-method U.S. Holder or an electing accrual-method U.S. Holder, the dollar amount of the euro purchase price will be determined by translating the euro paid at the dollar spot rate for euro on the
settlement date of the purchase. As described above, if a Holder is an accrual-method U.S. Holder and makes this election, the election must be applied consistently to all debt instruments from year
to year and cannot be changed without the consent of the IRS. If a Holder is an accrual-method U.S. Holder and does not make this election, the dollar equivalent of the purchase price will be
determined by translating that amount at the spot rate on the date of the purchase and foreign currency gain or loss (generally treated as ordinary income or loss) equal to the difference, if any,
between the dollar equivalent of the purchase price based on the spot rates in effect on the date of purchase and the settlement date will be generally recognized. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
Holder will recognize foreign currency gain or loss attributable to the movement in exchange rates between the time of purchase of the Note and the time of disposition, including the
sale, exchange, redemption or other disposition, of the Note. Gain or loss attributable to the movement of exchange rates will equal the difference between (1)&nbsp;the dollar value of the euro
purchase price for the Note, determined as of the date the Note is disposed of based on the dollar spot rate for euro in effect on
that date, and (2)&nbsp;the dollar value of the euro purchase price for such Note, determined on the date the Note was purchased based on the dollar spot rate for euro in effect on that date. Any
such gain or loss generally will be treated as ordinary income or loss, and generally will be U.S.-source gain or loss, and generally will not be treated as interest income or expense. A Holder will
recognize such foreign currency gain or loss to the extent such Holder has gain or loss, respectively, on the overall sale or taxable disposition of the Note. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the sale, exchange, redemption or other taxable disposition of a Note, a U.S. Holder generally will recognize gain or loss equal to the difference, if any, between (i)&nbsp;the
sum of all cash plus the fair market value of all other property received on such disposition (other than amounts properly attributable to accrued and unpaid interest, which, to the extent not
previously included in income, will be treated as ordinary interest income) and (ii)&nbsp;such U.S. Holder's adjusted tax basis in the Note. A U.S. Holder's adjusted tax basis in the Note will
generally equal the amount (in dollars as described above) such U.S. Holder paid for the Note. Subject to the discussion in the immediately preceding paragraph, any gain or loss recognized on the
sale, exchange, redemption or other taxable disposition of a Note generally will be capital gain or loss, and will be long-term capital gain or loss if, at the time of such disposition, the U.S.
Holder held the Note for a period of more than one year. Long-term capital gains recognized by certain non-corporate U.S. Holders, including individuals, are generally subject to tax at preferential
rates. The deductibility of capital losses is subject to limitations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information reporting generally will apply to payments of principal and interest on the Notes and payments of the proceeds from a sale or other
disposition (including retirement or a redemption) of the Notes unless the U.S. Holder is an exempt recipient. U.S. federal backup withholding (currently, at a rate of 24%) generally will apply to
such payments if the U.S. Holder fails to (i)&nbsp;provide a properly completed and executed IRS Form&nbsp;W-9 to the applicable withholding agent providing such U.S. Holder's correct taxpayer
identification number and complying with certain certification requirements or (ii)&nbsp;otherwise establish an exemption from backup withholding. U.S. Holders should consult their own tax advisors
regarding their qualification for an exemption from backup withholding, and the procedures for establishing such exemption, if applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=51,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=780995,FOLIO='S-49',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dk48901_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be refunded or allowed as a credit against the U.S. Holder's U.S. federal income
tax liability, if any, provided that the required information is furnished to the IRS in a timely manner. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reportable Transaction Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under applicable Treasury regulations, a U.S. Holder who participates in "reportable transactions" (as defined in the Treasury regulations) must
attach to such Holder's U.S. federal income tax return a disclosure statement on IRS Form&nbsp;8886. Under the relevant rules, a Holder may be required to treat a foreign currency exchange loss from
the Notes as a reportable transaction if this loss exceeds the relevant threshold in the regulations. Holders should consult their own tax advisors regarding the possible obligation to file IRS
Form&nbsp;8886 with respect to the ownership or disposition of the Notes, or any related transaction, including, without limitation, the disposition of any euro received. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain U.S. Federal Income Tax Considerations for Non-U.S. Holders  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payments of Interest  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below under "&#151;Information Reporting and Backup Withholding" and "&#151;FATCA," payments of interest
on the Notes to a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax under the "portfolio interest exemption," provided
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such interest is not effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (or, in the case
of an income tax treaty resident, is not attributable to a permanent establishment of the Non-U.S. Holder in the United States); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Non-U.S. Holder does not actually or constructively own 10% or more of the total combined voting power of all classes of our voting stock
within the meaning of the Code and the Treasury regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Non-U.S. Holder is not a "controlled foreign corporation" with respect to which we are a "related person" within the meaning of the Code; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Non-U.S. Holder is not a bank receiving the interest pursuant to a loan agreement entered into in the ordinary course of its trade or
business; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> either (1)&nbsp;the Non-U.S. Holder of the Notes provides the applicable withholding agent with a properly completed and executed IRS
Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as applicable, certifying, under penalties of perjury, that it is not a "United States person" (as defined in the Code) and providing its name and
address or (2)&nbsp;a financial institution that holds Notes on behalf of the Non-U.S. Holder certifies to the applicable withholding agent, under penalties of perjury, that it has received such
properly completed and executed IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as applicable, from the beneficial owner and provides the applicable withholding agent with a copy thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Non-U.S. Holder cannot satisfy the requirements of the "portfolio interest exemption" described above, payments of interest made to such Non-U.S. Holder will generally be subject to
U.S. federal withholding tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty, unless such interest is effectively connected with such Non-U.S. Holder's
conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment of the Non-U.S. Holder in the United States) and
such Non-U.S. Holder provides the applicable withholding agent with a properly completed and executed IRS Form&nbsp;W-8ECI. In order to claim an exemption from or reduction of withholding under an
applicable income tax treaty, a Non-U.S. Holder generally must provide to the applicable withholding agent a properly completed and executed IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as
applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=52,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=855164,FOLIO='S-50',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dk48901_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Non-U.S.
Holders should consult their own tax advisors regarding their entitlement to benefits under an applicable income tax treaty and the requirements for claiming any such benefits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
paid to a Non-U.S. Holder that is effectively connected with such Non-U.S. Holder's conduct of a trade or business within the United States (and, if required by an applicable
income tax treaty, is attributable to a permanent establishment of the Non-U.S. Holder in the United States), generally will not be subject to the U.S. federal withholding tax discussed above,
provided that the Non-U.S. Holder provides the applicable withholding agent with a properly completed and executed IRS Form&nbsp;W-8ECI. Instead, such interest generally will be subject to U.S.
federal income tax on a net-income basis at regular graduated U.S. federal income tax rates in the same manner as if such Non-U.S. Holder were a U.S. person. A Non-U.S. Holder that is a corporation
may be subject to an additional "branch profits tax" at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on its "effectively connected earnings and profits"
for the taxable year, subject to certain adjustments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale, Exchange, Redemption or Other Taxable Disposition of the Notes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below under "&#151;Information Reporting and Backup Withholding" and "&#151;FATCA," any gain realized on
the sale, exchange, redemption or other taxable disposition of a Note by a Non-U.S. Holder (other than amounts properly attributable to accrued and unpaid interest, which generally will be treated as
described under "&#151;Non-U.S. Holders&#151;Payments of Interest") generally will not be subject to U.S. federal income or withholding tax,
unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such gain is effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (and, if required by an
applicable income tax treaty, is attributable to a permanent establishment of the Non-U.S. Holder in the United States); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such Non-U.S. Holder is an individual who is present in the United States for a period of 183&nbsp;days or more during the taxable year of
the disposition and certain other conditions are met. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain
described in the first bullet point above generally will be subject to U.S. federal income tax on a net-income basis at regular graduated U.S. federal income tax rates in the same
manner as if such Non-U.S. Holder were a U.S. person. A Non-U.S. Holder that is a corporation may be subject to an additional "branch profits tax" at a rate of 30% (or such lower rate as may be
specified under an applicable income tax treaty) on its "effectively connected earnings and profits" for the taxable year, subject to certain adjustments. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain
described in the second bullet point above generally will be subject to U.S. federal income tax at a 30% rate (or such lower rate as may be specified under an applicable income tax
treaty), which gain may be offset by certain U.S.-source capital losses, if any, of the Non-U.S. Holder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally, we must report annually to the IRS and to each Non-U.S. Holder the amount of interest paid to such Non-U.S. Holder and the amount of
tax, if any, withheld with respect to such payments. These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable income tax treaty. This information
may also be made available to the tax authorities in the country in which a Non-U.S. Holder resides or is established pursuant to the provisions of a specific treaty or agreement with those tax
authorities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S.
backup withholding (currently, at a rate of 24%) is imposed on certain payments to persons that fail to furnish the information required under the U.S. information reporting rules.
Interest paid to a Non-U.S. Holder generally will be exempt from backup withholding if the Non-U.S. Holder provides the applicable withholding agent with a properly completed and executed IRS
Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as applicable, or otherwise establishes an exemption. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=53,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=322907,FOLIO='S-51',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dk48901_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Treasury regulations, the payment of proceeds from the disposition of a Note by a Non-U.S. Holder effected at a U.S. office of a broker generally will be subject to information
reporting and backup withholding, unless the Non-U.S. Holder provides a properly executed IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as applicable (or other applicable IRS Form&nbsp;W-8),
certifying such Non-U.S. Holder's non-U.S. status or by otherwise establishing an exemption. The payment of proceeds from the disposition of Notes by a Non-U.S. Holder effected at a non-U.S. office of
a U.S. broker or a non-U.S.
broker with certain specified U.S. connections generally will be subject to information reporting (but not backup withholding) unless such Non-U.S. Holder provides a properly executed IRS
Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as applicable (or other applicable IRS Form&nbsp;W-8), certifying such Non-U.S. Holder's non-U.S. status or by otherwise establishing an exemption.
Backup withholding will apply if the disposition is subject to information reporting and the broker has actual knowledge that the Non-U.S. Holder is a U.S. person. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be refunded or allowed as a credit against the Non-U.S. Holder's U.S. federal
income tax liability, if any, provided that the required information is furnished to the IRS in a timely manner. Non-U.S. Holders should consult their own tax advisors regarding the application of
these rules to their particular circumstances. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FATCA  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Sections&nbsp;1471 through 1474 of the Code and the Treasury regulations and administrative guidance thereunder, commonly referred to as
FATCA, U.S. federal withholding tax at a rate of 30% is imposed on U.S.-source interest paid on a Note and, subject to the regulatory relief described below, on the gross proceeds paid from the sale
or other disposition of a Note to (i)&nbsp;a "foreign financial institution" (as defined for this purpose) unless such institution is exempt from FATCA withholding pursuant to an applicable
intergovernmental agreement between the jurisdiction in which it is located and the United States, enters into an agreement with the U.S. government to collect and provide to the U.S. tax authorities
information regarding U.S. account holders of such institution (which would include certain equity and debt holders of such institution, as well as certain account holders that are foreign entities
with U.S. owners) or meets other exemptions or (ii)&nbsp;a foreign entity that is not a financial institution, unless such entity is exempt from FATCA withholding pursuant to an applicable
intergovernmental agreement between the jurisdiction in which it is located and the United States, provides the withholding agent with a certification identifying any substantial U.S. owners of the
entity (as defined for this purpose) or meets other exemptions. Under proposed U.S. Treasury regulations that may be relied upon pending finalization, the withholding tax on gross proceeds would be
eliminated and, consequently, FATCA withholding on gross proceeds paid from the sale or other disposition of a Note is not expected to apply. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
FATCA withholding is imposed, a Non-U.S. Holder that is not a foreign financial institution may under certain circumstances be eligible for a refund or credit of any amounts withheld
by filing certain information with the IRS. Prospective investors should consult their own tax advisors regarding the effects of FATCA on their investment in the Notes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk48901_underwriting"> </A>
<A NAME="toc_dk48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions contained in an underwriting agreement, dated as of the date of this prospectus supplement between us and
the underwriters named below, for whom Morgan Stanley&nbsp;&amp;&nbsp;Co. International&nbsp;plc, HSBC Bank&nbsp;plc and Merrill Lynch International are acting as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=54,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=884040,FOLIO='S-52',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dk48901_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>representatives,
we have agreed to sell to each underwriter, and each underwriter has severally agreed to purchase from us, the principal amount of Notes that appears opposite its name in the table
below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal<BR>
Amount of<BR>
20&nbsp;&nbsp;&nbsp;&nbsp;Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal<BR>
Amount of<BR>
20&nbsp;&nbsp;&nbsp;&nbsp;Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal<BR>
Amount of<BR>
20&nbsp;&nbsp;&nbsp;&nbsp;Notes </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Morgan Stanley&nbsp;&amp;&nbsp;Co. International&nbsp;plc</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HSBC Bank&nbsp;plc</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Merrill Lynch International</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&euro;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are offering the Notes subject to their acceptance of the Notes from us and subject to prior sale. The underwriting agreement provides that the obligations of the
several underwriters to pay for and accept delivery of the Notes offered by this prospectus supplement are subject to certain conditions. The underwriters are obligated to take and pay for all of the
Notes offered by this prospectus supplement if any such Notes are taken. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes
sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus supplement. Any Notes sold by the
underwriters to securities dealers may be sold at a discount from the initial public offering price of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal amount of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes and up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal amount of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes. Any such securities dealers may resell any Notes purchased from the underwriters to certain other brokers or dealers at a
discount from the initial public offering price of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal amount of the 20&nbsp;&nbsp;&nbsp;&nbsp;Notes and up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the principal
amount of the 20&nbsp;&nbsp;&nbsp;&nbsp;
Notes. If all the Notes are not sold at the initial offering price, the underwriters may change the offering price and the other selling terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Notes are new issues of securities with no established trading markets. We intend to apply for listing of the Notes for trading on the New York Stock Exchange. The listing
application will be subject to approval by the New York Stock Exchange. If such a listing is obtained, we have no obligation to maintain such listing, and we may delist the Notes at any time. In
addition, we have been advised by certain of the underwriters that they or certain of their affiliates intend to make markets in the Notes but are not obligated to do so and may discontinue market
making at any time without notice. No assurance can be given as to the liquidity of the trading markets for the Notes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate that our share of the total expenses of the offering, excluding underwriting discounts, will be approximately &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We have agreed to
indemnify the several underwriters against, or contribute to payments that the underwriters may be required to make in respect of, certain liabilities, including certain liabilities under the
Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect to deliver the Notes against payment for the Notes on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;&nbsp;business&nbsp;&nbsp;&nbsp;&nbsp;day following the date of
the pricing of the Notes
("T+&nbsp;&nbsp;&nbsp;&nbsp;"). Under Rule&nbsp;15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to a trade expressly agree
otherwise. Accordingly, purchasers who wish to trade Notes on the date of pricing will
be required, by virtue of the fact that the Notes initially will settle in T+&nbsp;&nbsp;&nbsp;&nbsp;, to specify alternative settlement arrangements to prevent a failed settlement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stabilization and Short Positions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the offering, the underwriters may purchase and sell Notes in the open market. These transactions may include short sales,
stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of Notes than they are required to purchase in
the offering. Stabilizing transactions consist of certain bids or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=55,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=681224,FOLIO='S-53',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dk48901_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>purchases
made for the purpose of preventing or retarding a decline in the market prices of the Notes while the offering is in progress. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters also may impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the
stabilizing manager has repurchased Notes sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
activities by the underwriters, as well as other purchases by the underwriters for their own accounts, may stabilize, maintain or otherwise affect the market prices of the Notes.
As a result, the prices of the Notes may be higher than the prices that otherwise might exist in the open market. If these activities are commenced, they may be discontinued by the underwriters at any
time without notice. These transactions may be effected in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Relationships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales
and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial
activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with
relationships with us, for which they received or will receive customary fees and expenses. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, certain of the underwriters or their respective affiliates may receive a portion of the net proceeds from this offering that may be used to redeem, satisfy and discharge or
prepay or repay at maturity, as the case may be, our indebtedness under the existing or future debt agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array
of investments and actively traded securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their
customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours or our affiliates (directly, as collateral securing other obligations or
otherwise) and/or persons and entities with relationships with us or our affiliates. Certain of the underwriters or their affiliates that have a lending relationship with us routinely hedge, and
certain other underwriters or their affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, such underwriters and their affiliates would
hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities, including potentially the Notes
offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the Notes offered hereby. The underwriters and their respective affiliates may also
communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at
any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=56,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=573887,FOLIO='S-54',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dk48901_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>resale
of the Notes must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any
amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of
the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or
consult with a legal advisor. Pursuant to section&nbsp;3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National
Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts of
interest in connection with this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dubai International Financial Centre  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
("DFSA"). This prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any
other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify
the information set forth herein and has no responsibility for the prospectus supplement. The Notes to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their
resale. Prospective purchasers
of the Notes offered should conduct their own due diligence on the Notes. If you do not understand the contents of this prospectus supplement you should consult an authorized financial advisor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes described herein are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made
available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client as defined in MiFID II; or (ii)&nbsp;a customer
within the meaning of the Insurance Mediation Directive, where that customer would not qualify as a professional client as defined in point (10)&nbsp;of Article&nbsp;4(1) of MiFID II; or
(iii)&nbsp;not a qualified investor as defined in the Prospectus Regulation. Consequently no key information document required by the PRIIPs Regulation for offering or selling the Notes or otherwise
making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful
under the PRIIPs Regulation. This prospectus supplement has been prepared on the basis that any offer of Notes in any Member State of the EEA will be made pursuant to an exemption under the Prospectus
Regulation from the requirement to publish a prospectus for offers of Notes. This prospectus supplement is not a prospectus for the purposes of the Prospectus Regulation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Australia  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No placement document, prospectus, product disclosure statement or other disclosure document (including as defined in the Corporations Act 2001
(Cth) ("Corporations Act")) has been or will be lodged with the Australian Securities and Investments Commission ("ASIC") or any other governmental agency, in relation to the offering. This prospectus
supplement does not constitute a prospectus, product disclosure statement or other disclosure document for the purposes of Corporations Act, and does not purport to include the information required
for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. No action has been taken which would permit an offering of the Notes in circumstances that would
require disclosure under Parts&nbsp;6D.2 or 7.9 of the Corporations Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=57,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=344793,FOLIO='S-55',FILE='DISK110:[19ZCG1.19ZCG48901]DK48901A.;9',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dm48901_1_56"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes may not be offered for sale, nor may application for the sale or purchase or any Notes be invited in Australia (including an offer or invitation which
is received by a person in Australia) and neither this prospectus supplement nor any other offering material or advertisement relating to the Notes may be distributed or published in Australia unless,
in each case: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
aggregate consideration payable on acceptance of the offer or invitation by each offeree or invitee is at least A$500,000 (or its equivalent in another currency,
in either case, disregarding moneys lent by the person offering the Notes or making the invitation or its associates) or the offer or invitation otherwise does not require disclosure to investors in
accordance with Part&nbsp;6D.2 or 7.9 of the Corporations Act;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
offer, invitation or distribution complied with the conditions of the Australian financial services license of the person making the offer, invitation or
distribution or an applicable exemption from the requirement to hold such license;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
offer, invitation or distribution complies with all applicable Australian laws, regulations and directives (including, without limitation, the licensing
requirements set out in Chapter&nbsp;7 of the Corporations Act);
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
offer or invitation does not constitute an offer or invitation to a person in Australia who is a "retail client" as defined for the purposes of
Section&nbsp;761G of the Corporations Act; and </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>such
action does not require any document to be lodged with ASIC or the ASX. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each underwriter has represented and agreed that: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>it
has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment
activity (within the meaning of Section&nbsp;21 of the FSMA) received by it in connection with the issue or sale of the Notes in circumstances in which Section&nbsp;21(1) of the FSMA does not
apply to the issuer; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>it
has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Notes in, from or otherwise
involving the United Kingdom. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap.&nbsp;32, Laws of Hong Kong), or (ii)&nbsp;to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap.
571, Laws of Hong Kong) and any rules made thereunder or (iii)&nbsp;in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance
(Cap. 32, Laws of Hong Kong), and no advertisement, invitation or document relating to the Notes may be issued or may be in the possession of any person for the purpose of issue (in each case whether
in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong)
other than with respect to Notes which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures
Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (the Financial Instruments and
Exchange Law) and each underwriter has agreed that it </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=58,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=952357,FOLIO='S-56',FILE='DISK110:[19ZCG1.19ZCG48901]DM48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dm48901_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>will
not offer or sell any Notes, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from
the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement and the accompanying prospectus have not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus supplement and the accompanying prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the
Notes may not be circulated or
distributed, nor may the Notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than
(i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the "SFA"), (ii)&nbsp;to a relevant person, or any person
pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
any other applicable provision of the SFA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the Notes are subscribed or purchased under Section&nbsp;275 by a relevant person which is: (a)&nbsp;a corporation (which is not an accredited investor), the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an
accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the
beneficiaries' rights and interest in that trust shall not be transferable for six months after that corporation or that trust has acquired the Notes under Section&nbsp;275 except: (1)&nbsp;to an
institutional investor under Section&nbsp;274 of the SFA or to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in
Section&nbsp;275 of the SFA; (2)&nbsp;where no consideration is given for the transfer; or (3)&nbsp;by operation of law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;309B(1)
Notification&#151;the Issuer has determined, and hereby notifies all persons (including all relevant persons (as defined in Section&nbsp;309A(1) of the
SFA)) that the Notes are prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations&nbsp;2018). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Switzerland  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement and the accompanying prospectus are not intended to constitute an offer or solicitation to purchase or invest in the
Notes described herein. The Notes may not be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other
exchange or regulated trading facility in Switzerland. Neither this prospectus supplement nor the accompanying prospectus nor any other offering or marketing material relating to the Notes constitutes
a prospectus as such term is understood pursuant to article&nbsp;652a or article&nbsp;1156 of the Swiss Code of Obligations, and neither this prospectus supplement nor the accompanying prospectus
nor any other offering or marketing material relating to the Notes may be publicly distributed or otherwise made publicly available in Switzerland. Neither this prospectus supplement nor the
accompanying prospectus nor any other offering or marketing material relating to the offering, the Notes or us have been or will be filed with or approved by any Swiss regulatory authority. In
particular, this prospectus supplement and the accompanying prospectus will not be filed with, and the offer of the Notes will not be supervised by, the Swiss Financial Market Supervisory Authority
("FINMA"), and the offer of the Notes has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes ("CISA"). The investor protection afforded to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=59,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=842746,FOLIO='S-57',FILE='DISK110:[19ZCG1.19ZCG48901]DM48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dm48901_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>acquirers
of interests in collective investment schemes under the CISA does not extend to acquirers of the Notes. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Taiwan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and
regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of
Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise
intermediate the offering and sale of the Notes in Taiwan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Arab Emirates  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notes have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai
International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities.
Further, this prospectus supplement does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public
offer. This prospectus supplement has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the DFSA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm48901_legal_matters"> </A>
<A NAME="toc_dm48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain legal matters related to the offering will be passed upon for us by Kirkland&nbsp;&amp; Ellis&nbsp;LLP, New York, New York. Certain
legal matters related to the offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP, New York, New York. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=60,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=619364,FOLIO='S-58',FILE='DISK110:[19ZCG1.19ZCG48901]DM48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<A NAME="page_dm48901_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm48901_experts"> </A>
<A NAME="toc_dm48901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our <A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115219000008/abbv-20181231x10k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018,</A> and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2018, as set forth in their reports, which are incorporated by reference in this
prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their
authority as experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audited historical financial statements of Allergan&nbsp;plc included in exhibit&nbsp;99.1 of AbbVie Inc.'s Current Report on Form&nbsp;8-K dated September&nbsp;16, 2019 have
been so incorporated in reliance on the report of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=61,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=832349,FOLIO='S-59',FILE='DISK110:[19ZCG1.19ZCG48901]DM48901A.;8',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g773827.jpg" ALT="LOGO" WIDTH="451" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>ABBVIE&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Debt Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the sale of one or more series of debt securities of AbbVie&nbsp;Inc., a Delaware corporation ("AbbVie," "we," "us"
or the "Company"), from time to time, on terms and at prices determined at the time the debt securities are offered for sale. The terms and prices will be described in more detail in one or more
supplements to this prospectus. Before investing, you should carefully read this prospectus and any related prospectus supplement or free writing prospectus. Prospectus supplements or free writing
prospectuses may also add, update, or change information contained in this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer and sell these securities to or through agents, underwriters, dealers, or directly to purchasers. The names of any agents, underwriters, or dealers and the terms of the
arrangements with such entities will be stated in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our securities involves risks. See "</B></FONT><FONT SIZE=3><B><I>Risk Factors</I></B></FONT><FONT SIZE=3><B>" in our
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/abbv-20171231x10k.htm">Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31,
2017</A>, in our subsequent periodic filings with the Securities and Exchange Commission (the "SEC") incorporated by reference in this prospectus and in the applicable prospectus supplement
or any related free writing prospectuses that we have authorized for use in connection with a specific offering.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>


<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
Prospectus dated September&nbsp;13, 2018. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=62,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=784280,FOLIO='blank',FILE='DISK112:[19ZCG2.19ZCG48902]BC48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg48902_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG48902A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg48902_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG48902_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48902_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48902_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi48902_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi48902_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48902_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48902_prospectus_summary"><FONT SIZE=2>3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48902_information_incorporated_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION INCORPORATED BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48902_information_incorporated_by_reference"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca48902_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca48902_where_you_can_find_more_information"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48902_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48902_risk_factors"><FONT SIZE=2>6</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48902_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48902_use_of_proceeds"><FONT SIZE=2>7</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cc48902_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIO OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cc48902_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>8</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_description_of_debt_securities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_description_of_debt_securities"><FONT SIZE=2>9</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_plan_of_distribution"><FONT SIZE=2>12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_legal_matters"><FONT SIZE=2>14</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ce48902_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ce48902_experts"><FONT SIZE=2>15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=63,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=377153,FOLIO='i',FILE='DISK112:[19ZCG2.19ZCG48902]BG48902A.;3',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bi48902_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48902_about_this_prospectus"> </A>
<A NAME="toc_bi48902_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the SEC using a "shelf" registration process. Using this process, we may
offer and sell debt securities described in this prospectus in one or more offerings from time to time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We have not authorized anyone to give any information or to make any representations concerning the debt securities we may offer except those which are in this
prospectus, any prospectus supplement that is delivered with this prospectus, any related free writing prospectus that we authorize, or any documents incorporated by reference into this prospectus. We
take no responsibility for, and can provide no assurance as to the reliability of, any other information or representations that others may give or make to you. This prospectus is not an offer to sell
or a solicitation of an offer to buy any securities other than the debt securities that are referred to in the prospectus supplement. This prospectus is not an offer to sell or a solicitation of an
offer to buy debt securities in any circumstances in which the offer or solicitation is unlawful. You should not interpret the delivery of
this prospectus, or any offer or sale of debt securities, as an indication that there has been no change in our affairs since the date of this prospectus.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides you with a general description of debt securities we may offer. Each time we sell debt securities described in this prospectus, we will provide a prospectus
supplement or free writing prospectus that will contain specific information about the terms of that offering and the debt securities being offered at that time. The prospectus supplement or free
writing prospectus also may add, update or change information contained in this prospectus, and any statement in this prospectus will be modified or superseded by any inconsistent statement in a
prospectus supplement or free writing prospectus. You should read both this prospectus and any prospectus supplement or free writing prospectus together with the additional information described under
the headings "Where You Can Find More Information" and "Information Incorporated by Reference." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should not assume that the information in this prospectus or any applicable prospectus supplement or any related free writing prospectus is accurate as of any date other than the
date on the cover of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=346087,FOLIO='1',FILE='DISK112:[19ZCG2.19ZCG48902]BI48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<A NAME="page_bi48902_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi48902_forward-looking_statements"> </A>
<A NAME="toc_bi48902_2"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, any prospectus supplement and the documents incorporated by reference, including the sections entitled "Prospectus Summary" and
"Risk Factors," contain certain forward-looking statements regarding business strategies, market potential, future financial performance and other matters. The words "believe," "expect," "anticipate,"
"project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date the statements were made. The matters discussed in these
forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the
forward-looking statements. Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and
expectations of AbbVie management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or
accomplished. Factors that could cause actual results or events to differ materially from those anticipated include the matters described in our
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/abbv-20171231x10k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2017</A> under "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of Operations." AbbVie does not undertake any obligation to update the forward-looking statements included in this
prospectus to reflect events or circumstances after the date of this prospectus, unless AbbVie is required by applicable securities law to do so. Please carefully review and consider the various
disclosures made in this prospectus or any prospectus supplement and in our reports filed with the SEC that attempt to advise interested parties of the risks and factors that may affect our business,
prospects and results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=752699,FOLIO='2',FILE='DISK112:[19ZCG2.19ZCG48902]BI48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca48902_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48902_prospectus_summary"> </A>
<A NAME="toc_ca48902_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all the information that you
should consider before investing in our debt securities. You should read the following summary together with the more detailed information regarding our Company, the securities being registered hereby
and our financial statements and notes thereto incorporated by reference into this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48902_abbvie_inc."> </A>
<A NAME="toc_ca48902_2"> </A>
<BR></FONT><FONT SIZE=2><B>  AbbVie&nbsp;Inc.    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's
most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood
cancers; virology, including hepatitis C&nbsp;virus (HCV) and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and
complications associated with cystic fibrosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical
specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
was incorporated in Delaware on April&nbsp;10, 2012. On January&nbsp;1, 2013, AbbVie became an independent company as a result of the distribution by Abbott Laboratories
("Abbott") of 100% of the outstanding common stock of AbbVie to Abbott's shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
also maintains an Internet site at </FONT><FONT SIZE=2><I>www.abbvie.com</I></FONT><FONT SIZE=2>. AbbVie's website and the information contained therein or connected thereto
shall not be deemed to be incorporated herein, and you should not rely on any such information in making an investment decision. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
address of AbbVie's principal executive offices is 1 North Waukegan Road, North Chicago, Illinois 60064. AbbVie's telephone number is 847-932-7900. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=66,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=249677,FOLIO='3',FILE='DISK112:[19ZCG2.19ZCG48902]CA48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<A NAME="page_ca48902_1_4"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48902_information_incorporated_by_reference"> </A>
<A NAME="toc_ca48902_3"> </A>
<BR></FONT><FONT SIZE=2><B>  INFORMATION INCORPORATED BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" the information we file with them, which means that we can disclose important information to you
by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will automatically update
and supersede information included or previously incorporated by reference into this prospectus from the date we file the document containing such information. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Except to the extent furnished and not filed with the SEC pursuant to Item&nbsp;2.02 or 7.01 of
Form&nbsp;8-K or as otherwise permitted by the SEC rules, we incorporate by reference the documents listed below and any future filings we will make with the SEC under Section&nbsp;13(a), 13(c),
14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), from the date of this prospectus until the completion of the offering in the relevant prospectus supplement to
which this prospectus relates or the offering is terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
documents we incorporate by reference into this prospectus are: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/abbv-20171231x10k.htm">Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2017</A> (including the information in Part&nbsp;III incorporated by reference from the Company's
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000104746918001843/a2234787zdef14a.htm">Definitive Proxy Statement on Schedule&nbsp;14A, filed on March&nbsp;19,
2018</A>);
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Quarterly
Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2018 and June&nbsp;30, 2018, as filed with the SEC on
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/abbv-20180331x10q.htm">May&nbsp;4, 2018</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/abbv-20180630x10q.htm">August&nbsp;7, 2018</A>, respectively; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Current
Reports on Form&nbsp;8-K as filed with the SEC on each of
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000020/abbv-20180331x8kclassic.htm">April&nbsp;26, 2018</A> (Item&nbsp;8.01 only),
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465918029415/a18-12281_118k.htm">May&nbsp;1, 2018</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465918031358/a18-13062_18k.htm">May&nbsp;8, 2018</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465918034532/a18-12281_178k.htm">May&nbsp;18, 2018</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000110465918055609/a18-24082_18k.htm">September&nbsp;6, 2018</A>. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is part of a registration statement on Form&nbsp;S-3 filed with the SEC under the Securities Act of 1933, as amended (the "Securities Act"). This prospectus does not
contain all of the information set forth in the registration statement. You should read the registration statement for further information about AbbVie and our debt securities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Documents
incorporated by reference into this prospectus are available from us, without charge, excluding all exhibits unless specifically incorporated by reference in the documents. You
may obtain documents incorporated by reference into this prospectus by writing to us at the following address or by calling us at the telephone number listed below: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>AbbVie&nbsp;Inc.<BR>
1 North Waukegan Road<BR>
North Chicago, Illinois 60064<BR>
Attention: Investor Relations<BR>
(847)&nbsp;932-7900<BR>
http://investors.abbvie.com </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized anyone to provide you with any information other than that contained or incorporated by reference into this prospectus, any accompanying prospectus or in any free
writing prospectus prepared by or on behalf of us or to which we have referred you and take no responsibility for, and can provide no assurance as to the reliability of, any other information that
others may give you. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any prospectus
supplement is accurate as of any date other than the date on the front page of those documents. </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=67,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=469567,FOLIO='4',FILE='DISK112:[19ZCG2.19ZCG48902]CA48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<A NAME="page_ca48902_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca48902_where_you_can_find_more_information"> </A>
<A NAME="toc_ca48902_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3 with respect to the debt securities offered hereby. This prospectus does
not contain all the information set forth in the registration statement, parts of which are omitted in accordance with the rules and regulations of the SEC. For further information with respect to us
and the debt securities offered hereby, reference is made to the registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document we file at the SEC's Public Reference Room in
Washington, D.C., located at 100&nbsp;F Street, N.E. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our SEC filings are also available to the public over
the internet from the SEC's website at www.sec.gov, or our website at www.abbvie.com. </FONT><FONT SIZE=2><B>Our website and the information contained therein or connected thereto shall not be deemed
to be incorporated into this prospectus or
registration statement of which this prospectus forms&nbsp;a part and you should not rely on any such information in making your investment decision.</B></FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=68,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=904809,FOLIO='5',FILE='DISK112:[19ZCG2.19ZCG48902]CA48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cc48902_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc48902_risk_factors"> </A>
<A NAME="toc_cc48902_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our debt securities involves risks. You should carefully consider the risks described under "Risk Factors" beginning on
page&nbsp;10 of our annual report on Form&nbsp;10-K for the period ended December&nbsp;31, 2017, which is incorporated by reference herein, as well as the other information contained or
incorporated by reference into this prospectus or any prospectus supplement hereto before making a decision to invest in our debt securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
business, financial condition, results of operations, and cash flows could be materially adversely affected by any of these risks. The market or trading price of our debt securities
could decline due to any of these risks. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business and operations or cause the
price of our debt securities to decline. In addition, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or
trends in future periods. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=69,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=956876,FOLIO='6',FILE='DISK112:[19ZCG2.19ZCG48902]CC48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_cc48902_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc48902_use_of_proceeds"> </A>
<A NAME="toc_cc48902_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as may be described otherwise in a prospectus supplement, we expect to use the net proceeds from the sale of the debt securities under
this prospectus for future acquisitions, stock repurchases, the repayment of indebtedness, capital expenditures, dividends, working capital, and any other general corporate purpose. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=70,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=784905,FOLIO='7',FILE='DISK112:[19ZCG2.19ZCG48902]CC48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_cc48902_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc48902_ratio_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_cc48902_3"> </A>
<BR></FONT><FONT SIZE=2><B>  RATIO OF EARNINGS TO FIXED CHARGES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below sets forth AbbVie's historical ratio of earnings to fixed charges for the periods indicated. We have not presented a ratio of
earnings to fixed charges and preferred stock dividends because we did not have preferred stock outstanding as of the date of this prospectus. The following table should be read in conjunction with
our consolidated financial statements and accompanying notes and Management's Discussion and Analysis of Financial Condition and Results of Operations included in our
<A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/abbv-20171231x10k.htm">Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31,
2017</A>, which are incorporated by reference into this prospectus. For further information, see Exhibit&nbsp;12.1 (Computation of Ratio of Earnings to Fixed Charges) to the registration
statement of which this prospectus forms&nbsp;a part. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>6-Months<BR>
Ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of earnings to fixed charges</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=71,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=1031744,FOLIO='8',FILE='DISK112:[19ZCG2.19ZCG48902]CC48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ce48902_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce48902_description_of_debt_securities"> </A>
<A NAME="toc_ce48902_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEBT SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description, together with the additional information that may be included in any applicable prospectus supplement and in any
related free writing prospectuses, summarizes the material terms and provisions of the debt securities that AbbVie may offer under this prospectus. While the terms summarized below will apply
generally to any debt securities that AbbVie may offer, the particular terms of any debt securities will be described in more detail in the applicable prospectus supplement. The terms of any debt
securities offered under a prospectus supplement may differ from the terms described below. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AbbVie
may issue debentures, notes or other evidences of indebtedness, which we refer to as "debt securities," from time to time in one or more distinct series. The debt securities may
be senior debt securities or subordinated debt securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
debt securities will be governed by an indenture, dated as of November&nbsp;8, 2012 (the "indenture"), between AbbVie and U.S. Bank National Association, as trustee. The indenture
is subject to and governed by the Trust Indenture Act of 1939, as amended (the "Trust Indenture Act"). The trustee under the indenture has two main roles:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> first, subject to some limitations, the trustee can enforce your rights against us if we default. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> second, the trustee performs certain administrative duties for us, which include sending you notices and, if the trustee also performs the
service of paying agent, interest payments. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
specific terms of debt securities being offered will be described in the applicable prospectus supplement. </FONT><FONT SIZE=2><I>As you read this section, please remember that the
specific terms of your debt securities as described in the applicable prospectus supplement will supplement and, if applicable, may modify or replace the general terms described in this section. If
there are any differences between the applicable prospectus supplement and this prospectus, the applicable prospectus supplement will control. Thus, the statements we make in this section may not
apply to your debt security.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
statements and descriptions in this prospectus or in any prospectus supplement or any document incorporated by reference into this prospectus or the applicable prospectus supplement
regarding provisions of debt securities and the indenture are summaries of those provisions, do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all
of the provisions of the debt securities and the indenture (including any amendments or supplements AbbVie may enter into from time to time which are permitted under the debt securities or the
indenture). You should read the summary below, the applicable prospectus supplement, the indenture and any related documents before making your investment decision. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will set forth the terms of the debt securities or any series thereof, including, if applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title of the debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any limit upon the aggregate principal amount of the debt securities of the series which may be authenticated and delivered under the
indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the person to whom any interest on the debt securities of the series shall be payable, if other than the person in whose name the debt
securities (or one or more predecessor debt securities) is registered at the close of business on the regular record date for such interest; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date or dates on which the principal of the debt securities of the series is payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate or rates at which the debt securities of the series shall bear interest, if any, or the method of calculating such rate or rates of
interest, and the date or dates from which such interest shall accrue; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=72,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=260261,FOLIO='9',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_ce48902_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dates on which any such interest shall be payable and the regular record date for any interest payable on any such date; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the place or places where the principal of and any premium and interest on the debt securities of the series shall be payable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the period or periods within which the price or prices at which and the terms and conditions upon which the debt securities of the series may
be redeemed, in whole or in part, at AbbVie's option; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the obligation, if any, of AbbVie to redeem, purchase or repay the debt securities of the series pursuant to any sinking fund or analogous
provisions or at the option of a holder thereof and the period or periods within which the price or prices at which and the terms and conditions upon which the debt securities of the series shall be
redeemed, purchased or repaid, in whole or in part, pursuant to such obligation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if other than denominations of $2,000 and any integral multiple of $1,000 in excess thereof, the denominations in which the debt securities of
the series shall be issuable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency, currencies or currency units in which payment of the principal of and any premium and interest on the debt securities of the
series shall be payable if other than the currency of the United States of America and the manner of determining the equivalent thereof in the currency of the United States of America for purposes of
the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the amount of payments of principal of or any premium or interest on any debt securities of the series may be determined with reference to
an index or formula, the manner in which such amounts shall be determined; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the principal of or any premium or interest on the debt securities of the series is to be payable, at the election of AbbVie or a holder
thereof, in one or more currencies or currency units other than that or those in which the debt securities are stated to be payable, the currency, currencies or currency units in which payment of the
principal of and any premium and interest on the debt securities of such series as to which such election is made shall be payable, and the periods within which and the terms and conditions upon which
such election is to be made; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the application, if any, of the provisions for the defeasance or covenant defeasance of the indenture to the debt securities of any series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the debt securities of the series shall be issued in whole or in part in the form of one or more global securities and, in such case,
the depositary with respect to such global security or securities and the circumstances under which any global security may be registered for transfer or exchange, or authenticated and delivered, in
the name of a person other than such depositary or its nominee; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if other than the principal amount thereof, the portion of the principal amount of the debt securities of the series which shall be payable
upon declaration of acceleration of the maturity thereof pursuant to the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether payment of any amount due under the debt securities will be guaranteed by one or more guarantors, including one or more of our
subsidiaries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the debt securities will be secured or unsecured; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the forms of the debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a discussion of any material United States federal income tax consequences of owning and disposing of the debt securities; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=73,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=820097,FOLIO='10',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_ce48902_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other terms of the debt securities of the series (which terms shall not be inconsistent with the provisions of the indenture, except as
permitted thereunder). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is part of a registration statement that provides that AbbVie may issue debt securities from time to time in one or more series under the indenture, in each case with the
same or various maturities, at par or at a discount. Unless otherwise indicated in the applicable prospectus supplement, the aggregate principal amount of debt securities that may be issued under the
applicable indenture is unlimited. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
indenture contains certain restrictive covenants that will apply to AbbVie and its subsidiaries unless otherwise indicated in the applicable prospectus supplement. Unless otherwise
indicated in the applicable prospectus supplement, the debt securities will not be listed on any securities exchange. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=74,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=203171,FOLIO='11',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_ce48902_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce48902_plan_of_distribution"> </A>
<A NAME="toc_ce48902_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell debt securities to or through underwriters and also directly to other purchasers or through agents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution of the debt securities offered under this prospectus may occur from time to time in one or more transactions at a fixed price or prices, which may be changed, or at
market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the sale of debt securities, underwriters may receive compensation from us or from purchasers of debt securities for whom they may act as agents in the form of
discounts, concessions, or commissions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underwriters
may sell debt securities to or through dealers, and such dealers may receive compensation in the form of discounts, concessions, or commissions from the underwriters, and/or
commissions from the purchasers for whom they may act as agents. Underwriters, dealers, and agents that participate in the distribution of debt securities offered under this prospectus may be
"underwriters," as defined in the Securities Act. Any underwriters or agents will be identified and their compensation (including underwriting discount) will be described in the applicable prospectus
supplement. The prospectus supplement will also describe the other terms of the offering, including any discounts or concessions allowed or re-allowed or paid to dealers and any securities exchanges
on which the offered securities may be listed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may have agreements with the underwriters, dealers, and agents to indemnify them against certain liabilities, including certain liabilities under the Securities Act, or to contribute
with respect to payments which the underwriters, dealers, or agents may be required to make as a result of those liabilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the applicable prospectus supplement indicates, we may authorize dealers or agents to solicit offers by certain institutions to purchase debt securities from us pursuant to contracts
that provide for payment and delivery on a future date. We must approve all institutions, but they may include, among others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commercial and savings banks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pension funds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> investment companies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> educational and charitable institutions. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
institutional purchaser's obligation under the contract will be subject to the condition that the purchase of the offered debt securities at the time of delivery is allowed by the
laws that govern such purchaser. The dealers and the agents will not be responsible for the validity or performance of the contracts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, the debt securities will be a new issue of securities and will have no established trading market. Any underwriters to whom debt securities are sold for public offering and
sale may make a market in the debt securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The debt securities may or may not
be listed on a national securities exchange. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=75,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=621417,FOLIO='12',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_ce48902_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with any offering of the debt securities offered under this prospectus, underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of
the debt securities or any other securities the prices of which may be used to determine payments on the debt securities. These transactions may include short sales, stabilizing transactions and
purchases to cover positions created by short sales. Short sales involve the sale by underwriters of a greater number of debt securities than the underwriters are required to purchase in the offering.
Stabilizing transactions consist of certain bids or purchases made for the purpose of preventing or retarding a decline in the market price of the debt securities while the offering is in progress. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underwriters
may also impose a penalty bid in any offering of debt securities offered under this prospectus and any prospectus supplement through a syndicate of underwriters. This occurs
when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the other underwriters have repurchased debt securities sold by or for the
account of such underwriter in stabilizing or short covering transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
activities by underwriters may stabilize, maintain or otherwise affect the market price of the debt securities offered under this prospectus and any prospectus supplement. As a
result, the price of such debt securities may be higher than the price that otherwise might exist in the open market. If these activities are commenced, they may be discontinued by underwriters at any
time. These transactions may be effected in the over-the-counter market or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=76,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=435725,FOLIO='13',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_ce48902_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce48902_legal_matters"> </A>
<A NAME="toc_ce48902_3"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated in the applicable prospectus supplement, legal matters in connection with the debt securities offered under this
prospectus will be passed upon for us by Wachtell, Lipton, Rosen&nbsp;&amp; Katz, New York, New York, and for any underwriters or agents by counsel named in the applicable prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=77,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=484082,FOLIO='14',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<A NAME="page_ce48902_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48902a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce48902_experts"> </A>
<A NAME="toc_ce48902_4"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our <A HREF="http://www.sec.gov/Archives/edgar/data/1551152/000155115218000014/abbv-20171231x10k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2017</A>, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, as set forth in their reports, which are incorporated by reference in this
prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as
experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=78,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=102917,FOLIO='15',FILE='DISK112:[19ZCG2.19ZCG48902]CE48902A.;4',USER='CHE108062',CD='12-SEP-2019;04:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g757503.jpg" ALT="LOGO" WIDTH="399" HEIGHT="70">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>&euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% SENIOR NOTES DUE 20  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> &euro;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% SENIOR NOTES DUE 20  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>Joint Book-Running Managers</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Morgan Stanley  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>(Global Coordinator)  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>BofA Merrill Lynch<BR>
HSBC  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>September&nbsp;&nbsp;&nbsp;&nbsp;, 2019  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=79,EFW="2239674",CP="ABBVIE INC.",DN="1",CHK=286044,FOLIO='blank',FILE='DISK110:[19ZCG1.19ZCG48901]HO48901A.;7',USER='CHE109696',CD='15-SEP-2019;17:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g757503.jpg
<DESCRIPTION>G757503.JPG
<TEXT>
begin 644 g757503.jpg
M_]C_X  02D9)1@ ! 0$!6@%:  #__@ I35),3%]'4D%02$E#4SI;04)"5DE%
M74%"0E9)15]+7TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M9^N2TIKM6W^EF83$=.HRQ8N4DI_%LE('3\K9K;,/6.96B$(A(2]B!CB5H#Y
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MV;$%,0\S>;J&.9>LR"9Q]-:.G7:)P,"@E%>OP48%U\V"Y,M?X?:R[XWI&O\
MCY[.9FR,ME.X5VE5.S(XUCQF:K27LG:92(B'C>U7Q2K,):%5="I*ULLZV*D=
M,5?*VV+R#Z#E*!?V;FH7N#W]ME<+ '?[?8/JW]P?<#X '8 [  !UR^<)T(_G
MNZA_\2V%OUWZ/G"="/Y[NH?_ !+86_7?H^<)T(_GNZA_\2V%OUWZ/G"="!$
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M=RAT]^P)E"/SA@K#.9X@Z"L5ES%F.,GQBC8WF;J,+Y4H2UMSHB/8?3%.5[$
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M"O4;Q$Y&UMV7P7:VDS$R#)X_K=G@96,=J'@KI2;/&*I)2\!*%2%[6KA77CV
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MI1*0PAYMX'K[*7(=_=_K?^567NF'AB@8HE$.X"'80'WA_B'P$!^ @/N$.X"
M@(ATK.\1OP'9!T?S!>=O=8*%*632?)<X_M=B85EDYDE=9+=//CNYBMV9DT;F
M/&XDDY5XHMCVVB Q4"5R6BV->/>,ZX^LT<W%ESO[O\4[D:GBZ=BLI:^R<O\
M*]@UWRHI*/Z4D[=+&5E9G'\JP=(S>,K-*%564>2%>.X@)=\9&1M%5L;AJW,2
MY!A;QJ.@]IA$CYSUQV=Q':?2,HX84IOCS,55 Q$TA!)I8E;5C6=5455,J4A7
M5-:ID(F!U7 &.!0VL+XNWAX,4IAN&P28F*4PD/@*>$Y!,4!$AQ)-G()B"(D,
M)#G()@$2',7L8>7[;LX>/XY[ ?0#8/TST?MNSAX_CGL!] -@_3/1^VZ^'?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g773827.jpg
<DESCRIPTION>G773827.JPG
<TEXT>
begin 644 g773827.jpg
M_]C_X  02D9)1@ ! 0$!A &$  #__@ U35),3%]'4D%02$E#4SI;04)"5DE%
M74%"0E9)15]53D-/051?1$Q?4$U37TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 40'# P$B
M  (1 0,1 ?_$ !\  0 " 04! 0$            *"PD"! 8'" $#!?_$ %<0
M   & @$" P($#1 (! <   $" P0%!@<(  D1"A(3%"$5,5C6%A@9&B(R05%A
M<7*7F",D,S<X.5-6=G=X@;6VT=<7-I*5EK&SQS2RM\$E)C5#=;3P_\0 ' $
M @(# 0$               <"!@,$!0$(_\0 31$  @$#!  $ 00*# X#
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M #N(@ !\8B/8 _K'FE10B1#J*&*0A"F.<QA I2E* F,8QC"!2E* ")C&$"E
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M0!R,-2T07/2$S8'K.E7L.:HM&XKGMR9V:-C4!1[*)Z0Y$J@^PE@Y9 'J]!.
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M7N913CP\*MS54]1-MNX2M4TSTSS4!G8R&+RN*S4F7Y%H'A8O'&?3'Y3JHXN
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MZU-,BA(X=PM.$:OVRRS9REZD5?\ **!&DM8 #ROX&G!"U=4S1Y(6MDK*IY\
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M53%<-FZ2Y2IE4!,KB9O-;05-XNU1!3AX)[E730N'90\4M5*\;!0,*&1E(4=
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MW?  %</-IF+'KBQ94+97LY.,$:LBN.?"B!@ 0]X#^ 0'[P@(#V$! ?<(" "
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M8I+O7C=%22(\CK'&K.[LJ(B@LSNQ"JJJ,EF8D   DD@#O7C,J*SL0JJ"S,Q
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M7'6!Z5&2^F7L/8(=K"V>P:P7-^XF\%Y==,7;V+&!>+*JACJZV)! 8QAD6E&
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MZB5335L7(DQAA*5!+".%F<!1Q4>\]E32)0Q-<+:TC/Q2-JBG;KY[QJ1+3.0
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M?_M_E#_[<<<-&MR7X@_$'_+GWCCAHTXXXX:-....&C3G36??VI+S_P#BD_\
M]A+CCF6#]WA_G8_^M=8I_P!PF_FI/^AM<RQW_J+3OY+0/]GH\YGQQR#_ #V_
MVF_2=>Q?N:_[*?\ 0NG'''(ZR:<<<<-&M"GVAOQ<U\<<-&G'''#1IS;+?;I_
CC_QXXX:\/M^5?TC6YXXXX:]TXXXX:-....&C3CCCAHU__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
